MannKind (MNKD) 10-K 27 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 09, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	MNKD
Entity Registrant Name	MANNKIND CORP
Entity Central Index Key	899,460
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		120,467,137
Entity Public Float			$ 103,912,399

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 43,946	$ 22,895
Restricted cash	4,409
Accounts receivable, net	2,789	302
Receivable from Sanofi		30,557
Inventory	2,657	2,331
Asset held for sale		16,730
Deferred costs from commercial product sales	405	309
Prepaid expenses and other current assets	3,010	4,364
Total current assets	57,216	77,488
Property and equipment, net	26,922	28,927
Other assets	437	648
Total assets	84,575	107,063
Current liabilities:
Accounts payable	6,984	3,263
Accrued expenses and other current liabilities	12,449	7,937
Facility financing obligation	52,745	71,339
Deferred revenue, net	3,038	3,419
Deferred payments from collaboration - current	250	1,000
Recognized loss on purchase commitments - current	12,131	5,093
Total current liabilities	87,597	92,051
Note payable to principal stockholder	79,666	49,521
Accrued interest - note payable to principal stockholder	2,347	9,281
Senior convertible notes	24,411	27,635
Recognized loss on purchase commitments - long term	97,585	95,942
Warrant liability		7,381
Deferred payments from collaboration - long term	500
Milestone rights liability and other liabilities	7,201	8,845
Total liabilities	299,307	290,656
Commitments and contingencies (Note 14)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2017 and 2016
Common stock, $0.01 par value - 280,000,000 and 140,000,000 shares authorized, 119,053,414 and 95,680,831 shares issued and outstanding at December 31, 2017 and 2016, respectively	1,192	957
Additional paid-in capital	2,638,992	2,553,039
Accumulated other comprehensive loss	(18)	(24)
Accumulated deficit	(2,854,898)	(2,737,565)
Total stockholders' deficit	(214,732)	(183,593)
Total liabilities and stockholders' deficit	$ 84,575	$ 107,063

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Undesignated preferred stock, par value	$ 0.01	$ 0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	280,000,000	140,000,000
Common stock, shares issued	119,053,414	95,680,831
Common stock, shares outstanding	119,053,414	95,680,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Net revenue - commercial product sales	$ 9,192	$ 1,895
Net revenue - collaboration	250	171,965
Revenue - other	2,303	898
Total revenues	11,745	174,758
Expenses:
Cost of goods sold	17,228	17,121	$ 64,745
Cost of revenue - collaboration		32,971
Research and development	14,118	14,917	29,674
Selling, general and administrative	74,959	46,928	40,960
Property and equipment impairment	203	1,259	140,412
Loss (gain) on foreign currency translation	13,641	(3,433)	2,697
(Gain) loss on purchase commitments	(215)	(2,265)	66,167
Total expenses	119,934	107,498	344,655
(Loss) income from operations	(108,189)	67,260	(344,655)
Other (expense) income:
Change in fair value of warrant liability	5,488	5,369
Interest income	293	85	18
Interest expense on notes	(9,494)	(15,576)	(21,231)
Interest expense on note payable to principal stockholder	(3,782)	(2,901)	(2,894)
(Loss) gain on extinguishment of debt	(1,611)	72,024	(1,049)
Other income (expense)	13	(597)	1,366
Total other (expense) income	(9,093)	58,404	(23,790)
(Loss) income before income tax expense	(117,282)	125,664	(368,445)
Provision for income taxes	51
Net (loss) income	$ (117,333)	$ 125,664	$ (368,445)
Net (loss) income per share - basic	$ (1.13)	$ 1.37	$ (4.54)
Net (loss) income per share - diluted	$ (1.13)	$ 1.36	$ (4.54)
Shares used to compute basic net (loss) income per share	104,245	92,053	81,233
Shares used to compute diluted net (loss) income per share	104,245	92,085	81,233

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (117,333)	$ 125,664	$ (368,445)
Other comprehensive income (loss):
Cumulative translation gain (loss)	6	(4)	(6)
Comprehensive (loss) income	$ (117,327)	$ 125,660	$ (368,451)

Statements of Stockholders' (De

Statements of Stockholders' (Deficit) - USD ($) $ in Thousands	Total	TEL AVIV STOCK EXCHANGE	Common Stock	Common StockTEL AVIV STOCK EXCHANGE	Additional Paid-in Capital	Additional Paid-in CapitalTEL AVIV STOCK EXCHANGE	Accumulated Other Comprehensive Income (Loss)	Deficit Accumulated During Development Stage
Beginning Balance at Dec. 31, 2014	$ (73,770)		$ 812		$ 2,420,216		$ (14)	$ (2,494,784)
Beginning Balance (in shares) at Dec. 31, 2014			81,212,000
Exercise of stock options	3,258		$ 3		3,255
Exercise of stock options (in shares)			340,000
Issuance of common shares from the release of restricted stock units	0		$ 1		(1)
Issuance of common shares from the release of restricted stock units (in shares)			144,000
Issuance of common shares pursuant to warrant exercises	10,123		$ 8		10,115
Issuance of common shares pursuant to warrant exercises (in shares)			843,000
Issuance of common shares under Employee Stock Purchase Plan	$ 887		$ 1		886
Issuance of common shares under Employee Stock Purchase Plan (in shares)	64,245		54,000
Stock-based compensation expense	$ 8,725				8,725
Restricted stock units taxes paid in cash	(1,856)				(1,856)
Capital contribution	40				40
Issuance of common shares pursuant to conversions of certain notes	7,926		$ 4		7,922
Issuance of common shares pursuant to conversions of certain notes (in shares)			375,000
Issuance of common stock for lender financing fees	160				160
Issuance of common stock for lender financing fees (in shares)			8,000
Discount on notes-for-stock exchange	169				169
Issuance of common stock	27,843	$ 34,710	$ 18	$ 28	27,825	$ 34,682
Issuance of common stock (Shares)			1,788,000	2,771,000
Return of loaned common stock			$ (18)		18
Return of loaned common stock (in shares)			(1,800,000)
Issuance of warrant liability	(202)				(202)
Reclassification of warrant liability to equity	109				109
Cumulative translation loss	(6)						(6)
Net (loss) income	(368,445)							(368,445)
Ending Balance at Dec. 31, 2015	(350,329)		$ 857		2,512,063		(20)	(2,863,229)
Ending Balance (in shares) at Dec. 31, 2015			85,735,000
Exercise of stock options	467		$ 1		466
Exercise of stock options (in shares)			55,000
Issuance of common shares from the release of restricted stock units	0		$ 1		(1)
Issuance of common shares from the release of restricted stock units (in shares)			131,000
Issuance of common shares under Employee Stock Purchase Plan	$ 426		$ 1		425
Issuance of common shares under Employee Stock Purchase Plan (in shares)	104,758		51,000
Stock-based compensation expense	$ 5,135				5,135
Restricted stock units taxes paid in cash	(165)				(165)
Issuance of direct placement - common stock and warrants (value)	50,000		$ 97		49,903
Issuance of direct placement - common stock and warrants (shares)			9,709,000
Issuance costs associated with direct placement	(2,037)				(2,037)
Issuance of warrant liability	(12,750)				(12,750)
Cumulative translation loss	(4)						(4)
Net (loss) income	125,664							125,664
Ending Balance at Dec. 31, 2016	(183,593)		$ 957		2,553,039		(24)	(2,737,565)
Ending Balance (in shares) at Dec. 31, 2016			95,681,000
Exercise of stock options	$ 24		$ 0		24
Exercise of stock options (in shares)	5,300		5,000
Issuance of common shares from the release of restricted stock units	$ 1		$ 2		(1)
Issuance of common shares from the release of restricted stock units (in shares)			135,000
Issuance of common shares under Employee Stock Purchase Plan	$ 236		$ 1		235
Issuance of common shares under Employee Stock Purchase Plan (in shares)	199,578		103,000
Stock-based compensation expense	$ 4,847				4,847
Restricted stock units taxes paid in cash	(127)				(127)
Issuance of common shares pursuant to conversions of certain notes	21,099		$ 115		20,984
Issuance of common shares pursuant to conversions of certain notes (in shares)			11,496,000
Issuance of direct placement — common stock	61,000		$ 102		60,898
Issuance of direct placement — common stock (shares)			10,167,000
Issuance costs associated with direct placement	(3,310)				(3,310)
Issuance of common stock	564		$ 2		562
Issuance of common stock (Shares)			173,000
Issuance costs associated with ATM placement	(17)				(17)
Reclassification of warrant liability to equity	1,893		$ 13		1,880
Reclassification of warrant liability to equity (in shares)			1,293,000
Amortization of shelf fees	(22)				(22)
Cumulative translation loss	6						6
Net (loss) income	(117,333)							(117,333)
Ending Balance at Dec. 31, 2017	$ (214,732)		$ 1,192		$ 2,638,992		$ (18)	$ (2,854,898)
Ending Balance (in shares) at Dec. 31, 2017			119,053,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (117,333,000)	$ 125,664,000	$ (368,445,000)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation, amortization and accretion	3,528,000	4,158,000	13,276,000
Stock-based compensation expense	4,847,000	5,135,000	8,725,000
Change in fair value of warrant liability	(5,488,000)	(5,369,000)
Loss (gain) on foreign currency translation	13,641,000	(3,433,000)	2,697,000
Loss (gain) on extinguishment of debt	1,611,000	(72,024,000)	1,049,000
Interest incurred through borrowings under Sanofi Loan Facility		4,478,000	1,652,000
Interest on note payable to principal stockholder	3,782,000	2,901,000	2,894,000
Series A warrant issuance cost		653,000
Other, net	100,000	19,000
(Gain) loss on sale, abandonment/disposal or impairment of property and equipment	203,000	1,259,000	140,582,000
(Gain) loss on purchase commitments	(215,000)	(2,265,000)	66,167,000
Write-off of inventory	2,971,000	0	36,104,000
Changes in operating assets and liabilities:
Accounts receivable, net	(2,487,000)	(302,000)
Receivable from Sanofi	30,557,000	(30,534,000)
Inventory	(3,297,000)	(2,331,000)	(26,434,000)
Receivable from collaboration			50,413,000
Deferred costs from commercial product sales	(96,000)	(309,000)
Deferred costs from collaboration		13,539,000	(13,539,000)
Prepaid expenses and other current assets	1,354,000	(346,000)	13,481,000
Other assets	188,000	361,000	150,000
Accounts payable	3,800,000	(12,118,000)	8,413,000
Accrued expenses and other current liabilities	2,932,000	348,000	(12,467,000)
Deferred revenue	(381,000)	3,419,000
Deferred payments from collaboration	(250,000)	(134,056,000)	950,000
Deferred sales from collaboration		(17,503,000)	17,067,000
Recognized loss on purchase commitments	(4,745,000)	40,566,000
Milestone rights liability and other liabilities			33,000
Net cash used in operating activities	(64,778,000)	(78,090,000)	(57,232,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1,144,000)	(10,285,000)
Net proceeds from sale of asset held for sale	16,651,000
Proceeds from sale of property and equipment	24,000	17,000	82,000
Net cash provided by (used in) investing activities	16,675,000	(1,127,000)	(10,203,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from direct placement of common stock	61,000,000	50,000,000
Issuance cost associated with direct placement	(3,310,000)	(2,690,000)
Principal payments on facility financing obligation	(4,000,000)	(5,000,000)
Payment of employment taxes related to vested restricted stock units	(127,000)	(165,000)	(1,858,000)
Proceeds from issuance of common stock		893,000	4,146,000
Exercise of warrants for common stock		0	10,123,000
Payment of senior convertible notes			(64,287,000)
Payment of debt issuance costs on senior convertible notes			(831,000)
Borrowings on note payable to principal stockholder	19,429,000
Milestone payment			(4,219,000)
Proceeds from issuance of common stock pursuant to at-the-market issuance	564,000		28,392,000
Issuance costs	(17,000)		(548,000)
Other	24,000		40,000
Net cash provided by financing activities	73,563,000	43,038,000	5,668,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	25,460,000	(36,179,000)	(61,767,000)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	22,895,000	59,074,000	120,841,000
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	48,355,000	22,895,000	59,074,000
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Income taxes paid in cash	51,000
Interest paid in cash, net of amounts capitalized	7,728,000	8,991,000	13,355,000
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payment of note obligations and interest through issuance of common stock	20,593,000		8,253,000
Non-cash construction in progress and property and equipment		588,000
Reclassification of deferred payments from collaboration to Sanofi Loan Facility and loss share obligation		5,174,000	59,337,000
Reclassification of property and equipment to asset held for sale		$ 17,294,000
Capitalization of interest on note payable to principal stockholder	10,716,000
Reclassification of warrant liability to additional paid-in capital	$ 1,880,000
TEL AVIV STOCK EXCHANGE
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock			36,142,000
Issuance costs			$ (1,432,000)

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Description of Business	1. Description of Business Business — MannKind Corporation and Subsidiaries (the “Company”) is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. The Company’s only approved product, Afrezza (insulin human) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the “FDA”) in June of 2014 to improve glycemic control in adults with diabetes. Afrezza became available by prescription in U.S. retail pharmacies in February 2015. Pursuant to a license and collaboration agreement (the “Sanofi License Agreement”) between the Company and Sanofi-Aventis U.S. LLC (“Sanofi”). Sanofi was responsible for global commercial, regulatory and development activities associated with Afrezza from August 2014 to April 2016. After a transition period during which Sanofi continued to fulfill orders for Afrezza, the Company assumed responsibility for worldwide development and commercialization of Afrezza and the Company began distributing MannKind-branded Afrezza to wholesalers in July 2016. During the second half of 2016, the Company utilized a contract sales organization to promote Afrezza while the Company focused its internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, the Company recruited its own specialty sales force to promote Afrezza to endocrinologists and certain high-prescribing primary care physicians. The Company’s current strategy for future commercialization of Afrezza outside of the United States, subject to receipt of the necessary foreign regulatory approvals, is to seek and establish regional partnerships in foreign jurisdictions where there are appropriate commercial opportunities. Basis of Presentation - The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is not currently profitable and has rarely generated positive net cash flow from operations. As of December 31, 2017, the Company had an accumulated deficit of $(2.9) billion. At December 31, 2017, the Company’s capital resources consisted of cash and cash equivalents of $43.9 million. The Company expects to continue to incur significant expenditures to support commercial manufacturing, sales and marketing of Afrezza and the development of product candidates in the Company’s pipeline. The facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (“Deerfield Private Design Fund”) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) that resulted in the issuance of 9.75% Senior Convertible Notes due 2019 (“2019 notes”) and the First Amendment to Facility Agreement and Registration Rights Agreement (the “First Amendment”) that resulted in the issuance of an additional tranche of 8.75% Senior Convertible Notes due 2019 (“Tranche B notes”) (see Note 7 — Borrowings) requires the Company to maintain at least $25.0 million in cash and cash equivalents or available borrowings under the loan arrangement, dated as of October 2, 2007, between the Company and The Mann Group LLC (“The Mann Group”) (as amended, restated, or otherwise modified as of the date hereof, “The Mann Group Loan Arrangement”), as of the last day of each fiscal quarter. On June 29, 2017, the Company entered into an Exchange and Third Amendment to the Facility Agreement (the “Third Amendment”) with Deerfield which, among other things, amended such financial covenant to provide that, if certain conditions are met, then the obligation to maintain at least $25.0 million in cash as of the end of each quarter will be reduced to $10.0 million as of August 31, 2017, September 30, 2017, October 31, 2017 and December 31, 2017 if certain conditions were met (see Note 7 — Borrowings). We met the conditions at each of these month-ends. As of December 31, 2017, the Company has $157.8 million principal amount of outstanding borrowings. The Company has entered into certain transaction related to these borrowings during 2017 and 2018 that are more fully described in Note 6 - Related Party Agreements, Note 7 – Borrowings and Note 20 – Subsequent Events. The Company’s available cash and financing sources will not be sufficient to meet its current and anticipated cash requirements, accordingly, these factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The Company plans to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with another company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development and commercialization of Afrezza and other product candidates and to support its other ongoing activities. The Company cannot provide assurances that such additional capital will be available on acceptable terms or at all. Successful completion of these plans is dependent on factors outside of the Company’s control. As such, management cannot be certain that such plans will be effectively implemented within one year after the date that the financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Reverse Stock Split - On March 1, 2017, following stockholder approval, the Company’s board of directors approved a 1-for-5 reverse stock split of its outstanding common stock. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, prior to March 3, 2017, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value. Correction of an Immaterial Error — Subsequent to the issuance of the Company’s financial statements for the year ended December 31, 2016 on Form 10-K, the Company determined that the common stock par value as of December 31, 2016 should not have been retrospectively adjusted for the impact of the reverse stock split on March 3, 2017 as described above. Management evaluated the materiality of the errors from a quantitative and qualitative perspective and concluded that this adjustment was not material to the Company’s previously issued financial statements. The Company has elected to revise the historical consolidated financial information presented herein in the consolidated balance sheet and statements of stockholders’ deficit to reflect the correction of this error for the prior periods presented. Since the revisions were not material, no amendments to previously filed reports were required. The revisions had the effect of decreasing common stock and increasing additional paid in capital by $3.8 million, $3.4 million, and $3.2 million as of December 31, 2016 and 2015 and January 1, 2015, respectively. Each affected individual line item within the consolidated statements of stockholders’ deficit relating to issuances of common shares for any reason and the return of loaned common stock in the years ended December 31, 2016 and 2015 have likewise been revised to decrease the common stock and increase the additional paid in capital attributable to each such transaction. Principles of Consolidation — The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Financial Statement Estimates — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies, and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The more significant estimates reflected in these accompanying consolidated financial statements include revenue recognition and gross-to-net adjustments, assessing long-lived assets for impairment, clinical trial expenses, inventory costing and recoverability, recognized loss on purchase commitment, milestone rights liability, stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. Revenue Recognition — Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When the accounting requirements for revenue recognition are not met, the Company defers the recognition of revenue by recording deferred revenue on the consolidated balance sheets until such time that all criteria are met. To date, the Company has had revenue from commercial sales of Afrezza, collaborations, sale of intellectual property and bulk insulin sales, which are described more fully below. Revenue Recognition – Net Revenue – Commercial Product Sales – The Company currently sells Afrezza through two channels: wholesale distributors and specialty pharmacies as further described below. The Company provides the right of return for unopened product for a period beginning six months prior to and ending twelve months after its expiration date. This right of return is provided to (1) the Company’s wholesale distributors and, through them, to its retail pharmacy customers, and (2) to its specialty pharmacies. Once the product has been prescribed and dispensed to the patient, any right of return ceases to exist. Sales of Afrezza through Wholesale Distributors - Between July 1, 2016 and December 15, 2016, the Company sold Afrezza to Integrated Commercialization Solutions Direct (“ICS”) and title and risk of loss transferred to ICS upon shipment. After December 15, 2016, ICS became a third party logistics provider and stopped taking title and risk of loss upon shipment of Afrezza to ICS. The Company sells Afrezza in the United States to wholesale pharmaceutical distributors through ICS, and ultimately to retail pharmacies, which are collectively referred to as “customers”. The current accounting guidance requires the Company to reliably estimate returns in order to recognize revenue upon shipment. While we can currently estimate returns within a range, it is not sufficiently precise to meet the current requirements. Accordingly, the Company defers recognition of revenue on Afrezza product shipments through wholesale distributors until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. Deferred revenue is presented net of deferred product sales discounts which are further described in Gross-to-net Adjustments Change in Estimate – In the fourth quarter of 2017, the Company obtained new and more comprehensive data regarding the inventory in the distribution channel. This data indicated that the amount of inventory in the distribution channel was less than previously estimated. Because the new data was more comprehensive than the data that was previously available to the Company, the Company adjusted the ending gross deferred revenue balance to match the new estimate. In addition to adjusting the gross deferred revenue balance, the Company adjusted the ending balances of deferred discounts and deferred cost of goods sold. The net effect of this change was an increase to net income of $1.2 million or $0.01 basic and diluted net income (loss) per share for the year ended December 31, 2017. Sales of Afrezza through Specialty Pharmacies - During the first quarter of 2017, the Company began selling Afrezza to a network of specialty pharmacies. Specialty pharmacies generally purchase product on demand. Title and risk of loss passes to the specialty pharmacies at shipment and our estimated returns are minimal. Therefore, the Company recognizes revenue for sales through specialty pharmacies at the time the product is shipped to the specialty pharmacies, net of as described below. For the year ended December 31, 2017, the net amount of revenue recognized from sales to specialty pharmacies was $0.5 million. For the years ended December 31, 2017 and 2016, Afrezza net revenue from commercial product sales consisted of $9.2 million and $1.9 million of net sales, respectively. As of December 31, 2017 and 2016, the ending balances for net deferred revenue, were $3.0 million and $3.4 million, on the Company’s consolidated balance sheets which are presented net of $1.5 million and $0.8 million in deferred gross-to-net adjustments, respectively. The December 31, 2016 deferred revenue balance includes $1.7 million of bulk insulin sales which is described more fully under the heading Revenue Recognition – Revenue – Other Gross-to-net Adjustments — Estimated gross-to-net adjustments for Afrezza include wholesaler distribution fees, prompt pay discounts, estimated rebates and chargebacks and patient discount and co-pay assistance programs, and are based on estimated amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of the Company’s agreements with its customers and the levels of inventory within the distribution and retail channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of gross revenue based on estimated utilization. If actual future results vary, the Company may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. The Company records product sales deductions in the consolidated statements of operations at the time product revenue is recognized. At December 31, 2017 and 2016, year to date total gross-to-net adjustments were approximately $3.4 million and $0.8 million, which represents 27% and 30% of gross revenue from product sales, respectively. Gross-to-net items that are unpaid at the end of each period are presented in discounts and allowances for commercial product sales in accrued expense and other current liabilities. Wholesaler Distribution Fees — The Company pays distribution fees to certain wholesale distributors based on contractually determined rates. The Company accrues the distribution fees on shipment to the respective wholesale distributors and recognizes the distribution fees as a reduction of revenue in the same period the related revenue is recognized. Prompt Pay Discounts — The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable and deferred revenue by the prompt pay discount amount (at the time of shipment to the wholesale distributor). The Company recognizes the cash discounts as a reduction of revenue in the same period the related revenue is recognized. Rebates and Chargebacks — Most of our rebates are contractual or legislatively mandated. Sales rebates include managed care, Medicare, Medicaid, and various other programs. The Company participates in federal and state government-managed Medicare and Medicaid rebate programs and, as such, is required to provide rebates under these programs. Chargebacks are discounts that occur when customers purchase directly from an intermediary wholesale purchaser. The Company accounts for these rebates and chargebacks by establishing an accrual based on contractual discount rates, expected utilization under each contract and an estimate of the amount of inventory in the distribution channel that will become subject to such rebates and chargebacks based on historical payor data provided by a third-party vendor along with additional data including forecasted participation rate. From that data, as well as input received from the commercial team, an estimated participation rate for each program is determined and applied at the rate for those sales. Any new information regarding changes in the programs’ regulations and guidelines or any changes in the Company’s Patient Discount and Co-Pay Assistance Programs — The Company offers discount card programs to patients for Afrezza in which patients receive discounts on their prescriptions or a reduction in their co-pay amounts that are reimbursed by the Company. The Company estimates the total amount that will be redeemed based on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. Deferred Costs from Commercial Product Sales — Deferred costs from commercial product sales represents the cost of product (including labor, overhead and shipping costs to third party logistics providers) shipped to wholesale distributors, but not dispensed by pharmacies to patients. If the Company estimates that inventory that has been shipped to wholesale distributors will be returned for credit because there is a risk of product expiry, deferred costs of commercial product sales is reduced and cost of goods sold is increased for the cost of such inventory. Revenue Recognition — Net Revenue — Collaborations — The Company enters into collaborations under which we must perform certain obligations and receive periodic payments. The Company evaluates the collaborations under the multiple element revenue recognition accounting guidance. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered elements have stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit. The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. The terms of and the accounting for the Company’s collaborations are described more fully in Note 8 — Collaboration Arrangements. Revenue Recognition — Revenue — Other — In 2017, Revenue-other consists of $1.7 million of revenue from bulk insulin sales and $0.6 million related to the sale of intellectual property to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd (“Fosun”), which is accounted for under the multiple-deliverable revenue recognition guidance and more fully described in Note 9 – Sale of Intellectual Property. Revenue from bulk insulin sales are recognized after delivery and customer acceptance of the bulk insulin. When the accounting requirements for revenue recognition of bulk insulin sales are not met, the Company defers recognition of revenue until such time that all criteria are met. As of December 31, 2016 the ending balance in deferred revenue included amounts related to bulk insulin sales of approximately $1.7 million. There was no deferred revenue related to bulk insulin sales as of December 31, 2017. Cost of Goods Sold — Cost of goods sold includes the costs related to Afrezza product dispensed by pharmacies to patients as well as the following costs which are expensed as incurred rather than capitalized into inventory: excess capacity labor and overhead, the impact of the annual revaluation of inventory and deferred costs of commercial sales to standard costs, and write-offs of inventory and deferred costs of commercial sales. Cash and Cash Equivalents — The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash to be cash equivalents. As of December 31, 2017 and 2016, cash equivalents were comprised of money market accounts with maturities less than 90 days from the date of purchase. Restricted Cash – The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. The Company presents amounts of restricted cash that will be available for use within twelve months of the reporting date as restricted cash in current assets. Restricted cash amounts that will not be available for use in the Company’s operations within twelve months of the reporting date are presented as restricted cash in long term assets. Concentration of Credit Risk — Financial instruments which potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market accounts, which are regularly monitored by management. Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. If the Company estimates that inventory that has been shipped to wholesale distributors will be returned for credit because there is a risk of product expiration, the Company reduces deferred revenue and increases the allowance for returns of such inventory. As of December 31, 2017 and 2016, the allowance for returns was de minimis. As of December 31, 2017 and 2016, there was no allowance for doubtful accounts. As of December 31, 2017 and 2016, the Company had three wholesale distributors representing approximately 93% and 95% of gross accounts receivable, respectively. Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company’s products based on management’s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as cost of goods sold. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand at December 31, 2017 and 2016. As a result of these assessments, the Company recorded a $3.0 million charge for the year ended December 31, 2017, to write-off inventory that may expire prior to sale. For the year ended December 31, 2016 there were no write-offs to inventory. For the year ended December 31, 2015, the Company recorded a charge of $39.3 million to record the inventory raw materials on hand at the lower of cost or net realizable value, inventory expiry and write-off other inventory related assets. Leases – The Company records rent expense for leases that contain scheduled rent increases on a straight-line basis over the lease term. When determining lease terms, the Company begins with the point at which the Company obtains control and possession of the leased property. State Research and Development Credit Exchange Receivable — The State of Connecticut provides certain companies with the opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for foregoing the carryforward of the research and development credits (the “State Program”). The State Program provides for an exchange of research and development income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. Estimated amounts receivable under the State Program are recorded as a reduction of research and development expenses. These amounts are included in prepaid expenses and other current assets on the consolidated balance sheets. During the year ended December 31, 2017, there was no research and development tax credit. During the years ended December 31, 2016 and 2015, research and development expenses were offset by research and development tax credits of $0.2 million and $0.7 million, respectively. Prepaid Expenses and Other Current Assets — As of December 31, 2017 and 2016, prepaid expenses and other current assets primarily consist of prepaid expenses for goods and services to be received and includes a certificate of deposit for $0.4 million as collateral as required by an agreement with the bank. Assets Held for Sale — The Company classifies long-lived assets anticipated to be sold within one year as held for sale at the lower of their carrying value or fair value less estimated selling costs. Property and Equipment — Property and equipment are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the term of the lease or the service lives of the improvements, whichever is shorter. Maintenance and repairs are expensed as incurred. Assets under construction are not depreciated until placed into service. Impairment of Long-Lived Assets — The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value may not be recoverable. If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss. The Company recorded an asset impairment of $0.2 million, $1.3 million and $140.6 million for the years ended December 31, 2017, 2016 and 2015, respectively (see Note 4 — Property and Equipment). Recognized Loss on Purchase Commitments — The Company assesses whether losses on long term purchase commitments should be accrued. Losses that are expected to arise from firm, non-cancellable, commitments for the future purchases are recognized unless recoverable. When making the assessment, the Company also considers whether it is able to renegotiate with its vendors. The recognized loss on purchase commitments is reduced as inventory items are received. If, subsequent to an accrual, a purchase commitment is successfully renegotiated, the gain is recognized in the Company’s consolidated statement of operations. During the year ended December 31, 2015, the Company recorded a loss on purchase commitments amounting to $116.2 million offset by $50 million expected to be recovered from Sanofi, primarily due to a long term purchase commitment for insulin raw materials. During the year ended December 31, 2016, the balance was adjusted for the recovery received from Sanofi, current purchases on the contracts and a reduction in the recognized loss related to amendments to purchase contracts. The balance of the recognized loss on insulin purchase commitments is $109.3 million as of December 31, 2017. No new contracts were identified in 2017 or 2016 requiring a new loss on purchase commitment accrual. Milestone Rights Liability — On July 1, 2013, in conjunction with the execution of the Facility Agreement, the Company issued Milestone Rights to Deerfield whereby the Company agreed to provide Deerfield with pre-specified Milestone Payments upon the achievement of 13 specific Milestone Events related to the commercial release and future cumulative net sales of Afrezza. The Company analyzed the Milestone Rights and determined that the agreement does not meet the definition of a freestanding derivative. Since the Company has not elected to apply the fair value option to the Milestone Rights Purchase Agreement, the Company recorded the Milestone Rights at their estimated initial fair value and accounted for the Milestone Rights as a liability. The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability will be remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, will be remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement will be recorded in the Company’s consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability will be reduced upon the settlement of each milestone payment. As a result, each milestone payment would be effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event (see Note 7 — Borrowings). As of December 31, 2017 and 2016, the remaining liability balance was $8.9 million. Fair Value of Financial Instruments —The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 — Significant inputs to the valuation model are unobservable. Income Taxes — The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. Income tax positions are considered for uncertainty. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. If a tax position does not meet the minimum statutory threshold to avoid payment of penalties, the Company recognizes an expense for the amount of the penalty in the period the tax position is claimed in the tax return of the Company. The Company recognizes interest accrued related to unrecognized tax benefits in income tax expense, if any. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets, deferred tax liabilities, and any valuation allowance recorded against deferred tax assets. Due to uncertainties related to the realization of the Company’s deferred tax assets as a result of its history of operating losses, a full valuation allowance has been established against the total deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed. See Note 16 – Income Taxes for disclosure on the tax laws enacted in December 2017. Contingencies — The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates. Stock-Based Compensation — Share-based payments to employees, including grants of stock options, restricted stock units, performance-based awards and the compensatory elements of employee stock purchase plans, are recognized in the consolidated statements of operations based upon the fair value of the awards at the grant date subject to an estimated forfeiture rate. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Restricted stock units are valued based on the market price on the grant date. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. Warrants — The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument and evaluation of sufficient authorized shares available to satisfy the obligations. Warrants classified as derivative liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized in the consolidated statements of operations. The Company estimates the fair value of its derivative liabilities using a third party valuation analysis that utilizes a Monte Carlo pricing valuation model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as expected volatility, expected life, yield and a risk-free interest rate. Warrants classified as equity are recorded within additional paid in capital at the issuance date and are not re-measured in subsequent periods, unless the underlying assumptions change to trigger liability accounting. As of December 31, 2017, the outstanding warrants were de minimis. At December 31, 2016, the outstanding warrants were $7.4 million. Comprehensive Income (Loss) — Other comprehensive income (loss) requires that all components of comprehensive income (loss) to be reported in the financial statements in the period in which they are recognized. Other comprehensive income (loss) includes certain changes in stockholders’ equity that are excluded from net income (loss). Specifically, the Company includes unrealized gains and losses on foreign exchange translation gains and losses resulting from translating cash and cash accounts in foreign currencies in accumulated other comprehensive loss on the consolidated balance sheets. Research and Development Expenses — Research and development expenses consist of costs associated with the clinical trials of the Company’s product candidates, development supplies and other development materials, compensation and other expenses for research and development personnel, costs for consultants and related contract research, facility costs, and depreciation. Research and development costs, which are net of any tax credit exchange recognized for the Connecticut state research and development credit exchange program, are expensed as incurred. Clinical Trial Expenses — Clinical trial expenses, which are reflected in research and development expenses in the accompanying consolidated statements of operations, result from obligations under contracts with vendors, consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The appropriate level of trial expenses are reflected in the Company’s consolidated financial statements by matching period expenses with period services and efforts expended. These expenses are recorded according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. Clinical trial accrual estimates are determined through discussions with internal clinical personnel and outside service providers as to the progress or state of completion of trials, or the services completed. Service provider status is then compared to the contractually obligated fee to be paid for such services. During the course of a clinical trial, the Company may adjust the rate of clinical expense recognized if actual results differ from management’s estimates. Bonuses – The Company accounts for bonu

Inventories

Inventories	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventories	3. Inventories Inventories consist of the following (in thousands): December 31, 2017 2016 Raw materials $ 572 $ — Work-in-process 1,273 2,120 Finished goods 812 211 Total inventory $ 2,657 $ 2,331 Work-in-process and finished goods as of December 31, 2017 and 2016 include conversion costs but not materials cost because the materials used in its production were previously written off. During the years ended December 31, 2017 and 2015, the Company recorded a write-down of inventory of approximately $3.0 million and $36.1 million, respectively, for inventory that was forecasted to become obsolete due to expiration which is recorded in costs of goods sold in the accompanying consolidated statements of operations. There was no write-down of inventory for the year ended December 31, 2016.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	4. Property and Equipment Property and equipment consist of the following (in thousands): Estimated Useful December 31, Life (Years) 2017 2016 Land — $ 875 $ 875 Buildings 39-40 17,389 17,389 Building improvements 5-40 34,957 34,957 Machinery and equipment 3-15 62,681 62,992 Furniture, fixtures and office equipment 5-10 3,556 3,556 Computer equipment and software 3 8,416 8,531 Construction in progress — — 202 127,874 128,502 Less accumulated depreciation (100,952 ) (99,575 ) Total property and equipment, net $ 26,922 $ 28,927 Depreciation and amortization expense related to property and equipment for the years ended December 31, 2017, 2016 and 2015, was $1.8 million, $2.4 million and $11.0 million, respectively. In 2015, in connection with the Company’s quarterly assessment of impairment indicators, the Company evaluated the continued lower than expected sales of Afrezza as reported by Sanofi throughout the fourth quarter of 2015, revised forecasts for sales of Afrezza provided by Sanofi in the fourth quarter of 2015 and level of commercial production in the fourth quarter of 2015, as well as the uncertainty associated with Sanofi’s announcement during the fourth quarter of their intent to reorganize their diabetes business. These factors indicated potentially significant changes in the timing and extent of cash flows, and the Company therefore determined that an impairment indicator existed in the fourth quarter of 2015. Based on the evaluation performed it was determined that the probability weighted undiscounted cash flows were not sufficient to recover the carrying value of the Danbury manufacturing facility. As a result of this assessment, the Company recorded, as of December 31, 2015, an impairment charge of $138.6 million for the Danbury manufacturing facility. An impairment of $0.7 million was charged to the individual asset groups for the year ended December 31, 2016, which is included in property and equipment impairment in the accompanying consolidated statements of operations, additionally with a $0.6 million impairment charge related to assets held for sale. On January 6, 2017, the Company and Rexford Industrial Realty, L.P. (“Rexford”) entered into an Agreement of Purchase and Sale and Joint Escrow Instructions (the “Purchase Agreement”), pursuant to which the Company agreed to sell and Rexford agreed to purchase certain parcels of real estate owned by the Company in Valencia, California and certain related improvements, personal property, equipment, supplies and fixtures (collectively, the “Property”) for $17.3 million. This asset in the amount of $16.7 million was classified as held for sale as of December 31, 2016. The sale and purchase of the Property for $17.3 million pursuant to the terms of the Purchase Agreement, as amended, was completed on February 17, 2017. Net proceeds were $16.7 million after deducting broker’s commission and other fees of approximately $0.6 million paid by the Company. Net proceeds received approximated the carrying value of the asset held for sale.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following (in thousands): December 31, 2017 2016 Salary and related expenses $ 7,260 $ 3,814 Current portion of milestone rights liability 1,643 — Professional fees 1,007 875 Discounts and allowances for commercial product sales 873 754 Sales and marketing services 147 144 Restructuring 362 1,376 Accrued interest 567 619 Other 590 355 Accrued expenses and other current liabilities $ 12,449 $ 7,937

Related-Party Arrangements

Related-Party Arrangements	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related-Party Arrangements	6. Related-Party Arrangements In October 2007, the Company entered into The Mann Group Loan Arrangement, which has been amended from time to time. On October 31, 2013, the promissory note underlying The Mann Group Loan Arrangement, described in the Company’s consolidated balance sheets as Note Payable to Principal Stockholder, On June 27, 2017, the Company entered into an agreement with The Mann Group, pursuant to which the parties agreed to, among other things, (i) capitalize $10.7 million of accrued and unpaid interest as of June 30, 2017, resulting in such amount being classified as outstanding principal under The Mann Group Loan Arrangement; (ii) advance to the Company approximately $19.4 million of cash, the remaining amount available for borrowing by the Company under The Mann Group Loan Arrangement after the foregoing capitalization of accrued and unpaid interest; and (iii) defer all interest payable on the outstanding principal until July 1, 2018, unless such payments are otherwise permitted under the subordination agreement with Deerfield, and subject to further deferral pursuant to the terms of the subordination agreement with Deerfield which terms are more fully disclosed below. Interest, at a fixed rate of 5.84%, is due and payable quarterly in arrears on the first day of each calendar quarter for the preceding quarter, or at such other time as the Company and The Mann Group mutually agree. The Mann Group can require the Company to prepay up to $200.0 million in advances that have been outstanding for at least 12 months, less approximately $105.0 million aggregate principal amount that has been cancelled in connection with two common stock purchase agreements. If The Mann Group exercises this right, the Company will have 90 days after The Mann Group provides written notice, or the number of days to maturity of the note if less than 90 days, to prepay such advances. However, pursuant to a letter agreement entered into in August 2010, The Mann Group has agreed to not require the Company to prepay amounts outstanding under the amended and restated promissory note if the prepayment would require the Company to use its working capital resources. In addition, The Mann Group entered into a subordination agreement with Deerfield pursuant to which The Mann Group agreed with Deerfield not to demand or accept any payment under The Mann Group Loan Arrangement until the Company’s payment obligations to Deerfield under the Facility Agreement have been satisfied in full. Subject to the foregoing, in the event of a default under The Mann Group Loan Arrangement, all unpaid principal and interest either becomes immediately due and payable or may be accelerated at The Mann Group’s option, and the interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum. All borrowings under The Mann Group Loan Arrangement are unsecured. The Mann Group Loan Arrangement contains no financial covenants. As of December 31, 2017 and 2016, the total principal amount outstanding under The Mann Group Loan Arrangement was $79.7 million and $49.5 million, respectively. As of December 31, 2017 and 2016, the Company had accrued unpaid interest related to the above note of $2.3 million and $9.3 million, respectively. Interest expense for the years ended December 31, 2017, 2016 and 2015 was $3.8 million, $2.9 million, and $2.9 million, respectively. As of December 31, 2017 there were no additional amounts available for future borrowings. As of December 31, 2016 there was $30.1 million available for future borrowings. In May 2015, the Company entered into a sublease agreement with the Alfred Mann Foundation for Scientific Research (the “Mann Foundation”), a California not for-profit corporation. The lease was for approximately 12,500 square feet of office space in Valencia, California, which expired in April 2017 and was renewed on a month-to-month basis at a rate of $20,000 per month until August 31, 2017 when the Company moved into its new corporate headquarters (see Note 14 — Commitments and Contingencies). Lease payments to the Mann Foundation for the years ended December 31, 2017, 2016 and 2015 were $0.2 million, $0.3 million, and $0.2 million, respectively. The Company has entered into indemnification agreements with each of its directors and executive officers, in addition to the indemnification provided for in its amended and restated certificate of incorporation and amended and restated bylaws (see Note 14 — Commitments and Contingencies). On October 10, 2017, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors and a charitable foundation (collectively, the “Purchasers”). Included in this offering were 166,600 shares issued to a charitable foundation associated with the Chairman of the Company’s board of directors.

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Borrowings	7. Borrowings Borrowings consist of the following (in thousands): December 31, 2017 2016 Facility Financing Obligation (2019 Notes and Tranche B Notes) Principal amount $ 54,407 $ 75,000 Unamortized debt issuance costs and debt discount (1,662 ) (3,661 ) Net carrying amount $ 52,745 $ 71,339 Senior Convertible Notes (2021 Notes) Principal amount $ 23,690 $ 27,690 Unamortized premium 721 426 Unaccreted debt issuance costs — (481 ) Net carrying amount $ 24,411 $ 27,635 Note payable to principal stockholder - net carrying amount $ 79,666 $ 49,521 Facility Financing Obligation (2019 Notes and Tranche B Notes) – As of December 31, 2017, there were $39.4 million principal amount of 2019 notes and $15.0 million principal amount of Tranche B notes outstanding. As of December 31, 2016, there were $55.0 million principal amount of 2019 notes and $20.0 million principal amount of Tranche B notes outstanding. The 2019 notes accrue interest at annual rate of 9.75% and the Tranche B notes accrue interest at an annual rate of 8.75%. Interest is paid quarterly in arrears on the last day of each March, June, September and December. On April 18, 2017, the Company entered into an Exchange Agreement with Deerfield pursuant to which the Company agreed to, among other things, (i) repay $4.0 million principal amount under the Tranche B notes; (ii) exchange $1.0 million principal amount under the Tranche B notes for 869,565 shares of the Company’s common stock (the “Tranche B Exchange Shares”); and (iii) exchange $5.0 million principal amount under the 2019 notes for 4,347,826 shares of the Company’s common stock (together with the “Tranche B Exchange Shares,” the “April Exchange Shares”). The exchange price for the Exchange Shares was $1.15 per share. The Company determined that, since the principal amount repaid and exchanged under the Tranche B notes and the principal amount exchanged under the 2019 notes represented the principal amount that would have otherwise become due and payable in May and July of 2017 under the Tranche B notes and 2019 notes, respectively, the extinguishment of the May and July 2017 payments was not considered to be a troubled debt restructuring. Accordingly, the Company accounted for the transaction by recording a loss on extinguishment of debt of $0.3 million at April 18, 2017 which was calculated as the difference between the reacquisition price and the net carrying value of the related debt. The reacquisition price was calculated using the $4.0 million cash repayment and the fair value of the April Exchange Shares on April 18, 2017. The fair value of the April Exchange Shares was determined to be $1.22 per share representing the closing trading price of the Company’s common stock on The NASDAQ Global Market on April 18, 2017. On June 29, 2017, the Company entered into the Third Amendment with Deerfield, pursuant to which the Company agreed to, among other things, (i) exchange $5.0 million principal amount under the Company’s 2019 notes for 3,584,230 shares of the Company’s common stock (the “June Exchange Shares”) at an exchange price of $1.395 per share and (ii) amend the Facility Agreement with Deerfield, to (A) defer the payment of $10.0 million in principal amount of the 2019 notes from the original July 18, 2017 due date to August 31, 2017, which was further deferred to October 31, 2017 upon the Company’s delivery on August 31, 2017 and October 30, 2017 of a written certification to Deerfield that certain conditions had been met, including that no event of default under the Facility Agreement had occurred, Michael E. Castagna remains the Company’s Chief Executive Officer, the Company received the advance from The Mann Group (see Note 6 — Related-Party Arrangements), the Company had at least $10.0 million in cash and cash equivalents on hand, no material adverse effect on the Company had occurred, the engagement letter between the Company and Greenhill & Co., Inc. (“Greenhill”) remained in full force and effect and Greenhill had remained actively engaged in exploring capital structure and financial alternatives on behalf of the Company in accordance with such engagement letter (collectively, the “Extension Conditions”), and (B) amend the Company’s financial covenant under the Facility Agreement to provide that, if the Extension Conditions remain satisfied, the obligation under the Facility Agreement to maintain at least $25.0 million in cash and cash equivalents as of the end of each quarter, was be reduced to $10.0 million as of August 31, 2017, September 30, 2017, October 31, 2017 and December 31, 2017 if certain conditions were met. We met the conditions at each of these month-ends. The Company determined that since the principal amount repaid and exchanged under the 2019 notes represented the principal amount that would have otherwise become due and payable under the 2019 notes, the $5.0 million prepayment was not considered to be a troubled debt restructuring. Accordingly, the Company accounted for the transaction by recording a loss on extinguishment of debt of $0.5 million on June 29, 2017 which was calculated as the difference between the reacquisition price and the net carrying value of the related debt. The net carrying value of the related debt includes the acceleration of the debt discount and issuance costs amounting to approximately $0.3 million as a result of the transaction. The reacquisition price was calculated using the fair value of the June Exchange Shares on June 29, 2017. The fair value of the Exchange Shares was determined to be $1.45 per share representing the closing trading price of the Company’s common stock on The NASDAQ Global Market on June 29, 2017. On October 23, 2017, the Company and MannKind LLC entered into a Fourth Amendment to the Facility Agreement, pursuant to which the parties (i) deferred the payment of $10.0 million in principal amount (the “October Payment”) of the Facility Financing Obligation from October 31, 2017 to January 15, 2018 (further extended to January 19 ,2018 under the Fifth Amendment and May 6, 2018 under the Sixth Amendment to the Facility Agreement – See Note 20 - Subsequent Events), with the Company depositing an amount of cash equal to the October Payment into an escrow account until the October Payment has been satisfied in full (subject to early release to the extent that portions of the October Payment are satisfied through the exchange of principal for shares of the Company’s common stock), and (ii) amended and restated the Facility Financing Obligation and the Tranche B notes to provide that Deerfield may convert the principal amount under such notes from time to time into an aggregate of up to 4,000,000 shares of the Company’s common stock after the effective date of the Fourth Amendment. The conversion price will be the greater of (i) the average of the volume weighted average price per share of the Company’s common stock for the three trading day period immediately preceding the date of any election by Deerfield to convert principal amounts of such notes and (ii) $3.25 per share, subject to adjustment under certain circumstances. Any conversions of principal by Deerfield under such notes will be applied first to reduce the October Payment, and after the October Payment has been satisfied, to reduce other principal payments due under the 2019 notes or the Tranche B notes. The Company determined that the Fourth Amendment did not include any concessions and that the addition of the conversion option was not substantive and therefore it was not considered to be a troubled debt restructuring. Accordingly, the Company accounted for the transaction as a modification. On November 6, 2017 Deerfield converted 1,720,846 shares under the conversion feature at a price of $3.25/share, redeeming $5,592,750 of principal. As of December 31, 2017, there was $39.4 million principal amount of 2019 notes and $15.0 million principal amount of Tranche B notes outstanding. The 2019 notes accrue interest at an annual rate of 9.75% and the Tranche B notes accrue interest at an annual rate of 8.75%. Interest is paid quarterly in arrears on the last day of each March, June, September and December. The Facility Financing Obligation principal repayment schedule is comprised of payments which began on July 1, 2016 and end on December 9, 2019. As of December 31, 2017, future payments for the years ending December 31, 2018, and 2019 are $24.4 million and $30.0 million, respectively. In connection with the Facility Agreement, on July 1, 2013, the Company entered into a Milestone Rights Purchase Agreement (the “Milestone Agreement”) with Deerfield and Horizon Santé FLML SÁRL (collectively, the “Milestone Purchasers”), which requires the Company to make contingent payments to the Milestone Purchasers, totaling up to $90.0 million, upon the Company achieving specified commercialization milestones (the “Milestone Rights”). The Milestone Rights were initially recorded as a short-term liability equal to $3.2 million included in accrued expenses and other current liabilities and a long-term liability equal to $13.1 million included in other liabilities in the accompanying consolidated balance sheets. During the first quarter of 2015, a milestone triggering event was achieved following the Afrezza launch on February 3, 2015, which resulted in a $5.8 million incremental charge to interest expense due to the increase in carrying value of the liability to the $10.0 million milestone payment made in February 2015. As of December 31, 2017 and 2016, the remaining milestone rights liability balance was $8.9 million. The Company currently estimates that it will reach the next milestone in the third quarter of 2018, at which point the Company will be required to make a $5 million payment. The carrying value of the milestone rights liability related to this $5 million payment is $1.6 million, which represents the fair value related to this payment that was determined in 2013 (the most recent measurement date). Accordingly, $1.6 million in value related to the next milestone payment was recorded in accrued expenses and other current liabilities as of December 31, 2017. Furthermore, $7.2 million and $8.9 million was recorded in milestone rights liability and other liabilities, which is non-current, in the accompanying consolidated balance sheets as of December 31, 2017 and 2016, respectively. Accretion of debt issuance cost and debt discount in connection with the Facility Agreement does not include the acceleration of the debt discount and issuance costs related to the transactions disclosed above as the amounts were included in the loss on extinguishment of debt in the consolidated statement of operations. Accretion of debt issuance cost and debt discount during the years ended December 31, 2017, 2016 and 2015 were as follows (in thousands): December 31, 2017 2016 2015 Accretion expense - debt issuance cost $ 31 $ 35 35 Accretion expense - debt discount $ 1,700 $ 1,722 1,553 The Facility Agreement includes customary representations, warranties and covenants, including a restriction on the incurrence of additional indebtedness. As discussed in Note 1 – Description of Business, the Company will need to raise additional capital to support its current operating plans. Due to the uncertainties related to maintaining sufficient resources to comply with the aforementioned covenant, the Facility Financing Obligation has been classified as a current liability in the accompanying consolidated balance sheets as of December 31, 2017 and 2016. In the event of non-compliance, Deerfield may declare all or any portion of the Facility Financing Obligation to be immediately due and payable. Milestone Rights — The Milestone Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of the Milestone Agreement. The Company initially recorded the Milestone Rights at their estimated fair value. Security Agreement — In connection with the Facility Agreement and Milestone Agreement, the Company and its subsidiary, MannKind LLC, entered into a Guaranty and Security Agreement (the “Security Agreement”) with Deerfield and Horizon Santé FLML SÁRL (collectively, the “Purchasers”), pursuant to which the Company and MannKind LLC each granted the Purchasers a security interest in substantially all of their respective assets, including respective intellectual property, accounts receivables, equipment, general intangibles, inventory and investment property, and all of the proceeds and products of the foregoing. The Security Agreement includes customary covenants by the Company and MannKind LLC, remedies of the Purchasers and representations and warranties by the Company and MannKind LLC. The security interests granted by the Company and MannKind LLC will terminate upon repayment of the Facility Financing Obligation, if applicable, in full. Embedded Derivatives — The Company identified and evaluated a number of embedded features in the notes issued under the Facility Agreement to determine if they represented embedded derivatives that are required to be separated from the notes and accounted for as freestanding instruments. The Company analyzed the Tranche B notes and identified embedded derivatives which required separate accounting. All of the embedded derivatives were determined to have a value as of December 31, 2017 and 2016. Senior Convertible Notes Due 2021 — On October 23, 2017, the Company entered into exchange agreements with the holders of the Company’s 5.75% Senior Convertible Notes due 2018 (the “2018 notes”), pursuant to which the Company agreed to exchange all of the outstanding 2018 notes in the aggregate principal amount of $27,690,000 for (i) 23,690,000 aggregate principal amount of Senior Convertible notes due 2021 (the “2021 notes”) and (ii) an aggregate of 973,236 shares of its common stock. In addition, the conversion rate was adjusted from $34 per share to $5.15 per share. The 2021 notes were issued at the closing of the exchange on October 23, 2017. The Company analyzed this exchange and concluded that the exchange represents an extinguishment of the 2018 notes and recorded a $0.8 loss on extinguishment of debt. In addition unamortized debt issuance costs of $0.3 million and unamortized debt premium of $0.2 million were also written-off during the last quarter of fiscal year 2017. The 2021 notes are the Company’s general, unsecured, senior obligations, except that they are subordinated in right of payment to the Facility Financing Obligation. The 2021 notes rank equally in right of payment with the Company’s other unsecured senior debt. The 2021 notes bear interest at the rate of 5.75% per year on the principal amount, payable semiannually in arrears in cash or, at the option of the Company if certain conditions are met, in shares of the Company’s common stock (the “Interest Shares”), on February 15 and August 15 of each year, beginning February 15, 2018, with interest accruing from August 15, 2017. The aggregate number of Interest Shares that the Company may issue may not exceed 13,648,300, unless the Company receives stockholder approval to issue Interest Shares in excess of such number in accordance with the listing standards of the NASDAQ Global Market. Accrued interest related to these notes is recorded in accrued expenses and other current liabilities on the accompanying consolidated balance sheets. The 2021 notes are convertible, at the option of the holder, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Company’s common stock at an initial conversion rate of 194.1748 shares per $1,000 principal amount of 2021 notes, which is equal to the initial conversion price of approximately $5.15 per share. The conversion rate is subject to adjustment under certain circumstances described in an indenture governing the 2021 notes. If the Company undergoes certain fundamental changes, except in certain circumstances, each holder of 2021 notes will have the option to require the Company to repurchase all or any portion of that holder’s 2021 notes. The fundamental change repurchase price will be 100% of the principal amount of the 2021 notes to be repurchased plus accrued and unpaid interest, if any. The Company may elect at its option to cause all or any portion of the 2021 notes to be mandatorily converted in whole or in part at any time prior to the close of business on the business day immediately preceding the maturity date, if the last reported sale price of its common stock exceeds 120% of the conversion price then in effect for at least 10 trading days in any 20 consecutive trading day period, ending within five business days prior to the date of the mandatory conversion notice. The redemption price is equal the sum of 100% of the principal amount of the 2021 notes to be redeemed, plus accrued and unpaid interest. Under the terms of the indenture, the conversion option can be net-share settled and the maximum number of shares that could be required to be delivered under the indenture is fixed and less than the number of authorized and unissued shares less the maximum number of shares that could be required to be delivered during the term of the 2021 notes under existing commitments. Applying the Company’s sequencing policy, the Company performed an analysis at the time of the offering of the 2021 notes and each reporting date since and has concluded that the number of available authorized shares at the time of the offering and each reporting date since was sufficient to deliver the number of shares that could be required to be delivered during the term of the 2021 notes under existing commitments. The 2021 notes provide that upon an acceleration of certain indebtedness, including the 2019 notes and the Tranche B notes issued to Deerfield pursuant to the Facility Agreement, the holders may elect to accelerate the Company’s repayment obligations under the notes if such acceleration is not cured, waived, rescinded or annulled. As a result of the exchange of the 2021 notes during the last quarter of 2017, Accretion of debt issuance costs in connection with the 2018 notes during the years ended December 31, 2017 and 2016 was $0.2 million and $0.3 million, respectively. Amortization of the 2018 notes premium during the years ended December 31, 2017 and 2016 was $0.2 million and $0.2 million, respectively. Amortization of the 2021 notes premium during the year ended December 31, 2017 was $0.03 million. Refer to Note 6 — Related-Party Arrangements for information regarding the Note payable to principal stockholder.

Collaboration Arrangements

Collaboration Arrangements	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaboration Arrangements	8. Collaboration Arrangements Receptor Collaboration and License Agreement — On January 20, 2016, the Company entered into a Collaboration and License Agreement (the “CLA”) with Receptor Life Sciences, Inc. (“Receptor”) pursuant to which the Company performed initial formulation studies on compounds identified by Receptor and Receptor obtained the option to acquire an exclusive license to develop, manufacture and commercialize certain products that use the Company’s technology to deliver the compounds via oral inhalation. The Company received $0.4 million in nonrefundable payments in 2016 prior to Receptor exercising the option. On December 30, 2016, following successful completion of the studies, Receptor exercised its option and paid the Company a $1.0 million nonrefundable option exercise and license fee. Under the CLA, the Company may receive the following additional payments: • Nonrefundable milestone payments upon the completion of certain technology transfer activities and the achievement of specified sales targets; • Royalties upon Receptor’s and its sublicensees’ sale of the product; and • Milestones upon total worldwide sales reaching certain agreed upon levels. The Company evaluated the accounting for the payments received in 2016 under the multiple element accounting guidance and determined that the $0.4 million in payments received prior to Receptor exercising its option are separable from the other elements of the agreement and represented payments to offset costs incurred. Therefore, those payments reduced the Company’s research and development expense in 2016. The $1.0 million license fee received in 2016 does not have standalone value from the follow-on transfer of technology. Therefore, the license fee was recorded in deferred payments from collaboration as of December 31, 2016 and will be recognized in net revenue — collaboration over four years. Recognized revenue related to this license agreement amounted to $0.3 million for the year ended December 31, 2017. See Note 2 — Summary of Significant Accounting Policies for additional information on the Company’s accounting for multiple element arrangements. On March 15, 2017, the Company entered into a Manufacturing and Supply Agreement with Receptor pursuant to which the Company will provide certain raw materials to Receptor. On March 16, 2017, the Company agreed to provide certain additional research and formulation consulting services to Receptor. For the year ended December 31, 2017 the additional research and formulation services to Receptor were de minimis. Sanofi License Agreement and Sanofi Supply Agreement — On August 11, 2014, the Company entered into a license and collaboration agreement with Sanofi (“Sanofi License Agreement”), pursuant to which Sanofi was responsible for global commercial, regulatory and development activities for Afrezza. The Company manufactured Afrezza at its manufacturing facility in Danbury, Connecticut to supply Sanofi’s demand for the product pursuant to a supply agreement dated August 11, 2014 (the “Sanofi Supply Agreement”). During the term of the Sanofi License Agreement, worldwide profits and losses were determined based on the difference between the net sales of Afrezza and the costs and expenses incurred by the Company and Sanofi that were specifically attributable or related to the development, regulatory filings, manufacturing, or commercialization of Afrezza. These profits and losses were shared 65% by Sanofi and 35% by the Company. On April 4, 2016 the Sanofi License Agreement was terminated. On April 5, 2016, the Company assumed responsibility for the worldwide development and commercialization of Afrezza from Sanofi. Under the terms of the transition agreement, Sanofi continued to fulfill orders for Afrezza in the United States until the Company began distributing MannKind-branded Afrezza product to major wholesalers in July 2016. The Company analyzed the agreements entered into with Sanofi at their inception and determined that prior to December 31, 2015, because the Company did not have the ability to estimate the amount of costs that would potentially be incurred under the loss share provision related to the Sanofi License Agreement and the Sanofi Supply Agreement, the Company recorded the $150.0 million up-front payment and the two milestone payments of $25.0 million each as deferred payments from collaboration. In addition, as of December 31, 2015, the Company had recorded $17.5 million in Afrezza product shipments to Sanofi as deferred sales from collaboration and recorded $13.5 million as deferred costs from collaboration. Deferred costs from collaboration represented the costs of product manufactured and shipped to Sanofi, as well as certain direct costs associated with a firm purchase commitment entered into in connection with the collaboration with Sanofi. During the third quarter of 2016, Sanofi provided information to the Company to enable it to reasonably estimate the remaining costs under the Sanofi License Agreement and the Sanofi Supply Agreement. Accordingly, the fixed or determinable fee requirement for revenue recognition was met and there were no future obligations to Sanofi. Therefore, the Company recognized $172.0 million of net revenue — collaboration for the year ended December 31, 2016. The revenue recognized includes the upfront payment of $150.0 million and the two milestone payments of $25.0 million each, net of $64.9 million of net loss share with Sanofi, as well as $17.5 million in sales of Afrezza and $19.4 million from sales of bulk insulin, both to Sanofi. These payments and sales were made pursuant to the contractual terms of the agreements with Sanofi. Sanofi Loan Facility — On September 23, 2014, the Company entered into a senior secured revolving promissory note and a guaranty and security agreement (collectively, the “Sanofi Loan Facility”) with an affiliate of Sanofi, which provided the Company with a secured loan facility of up to $175.0 million to fund the Company’s share of net losses under the Sanofi License Agreement. Advances under the Sanofi Loan Facility bore interest at a rate of 8.5% per annum and were payable in-kind and compounded quarterly and added to the outstanding principal balance under the Sanofi Loan Facility. The Company’s total portion of the loss sharing was $57.7 million for the year ended December 31, 2015, of which $44.5 million was borrowed under the Sanofi Loan Facility as of December 31, 2015. Subsequent to December 31, 2015, the Company borrowed $17.9 million under the Sanofi Loan Facility to finance the portion of the Company’s loss share for the quarters ended December 31, 2015 and March 31, 2016. The total amount owed to Sanofi at September 30, 2016 was $71.2 million, which included $5.8 million of paid-in-kind interest. On November 9, 2016, the Company entered into a settlement agreement with Sanofi (the “Settlement Agreement”). Under the terms of the Settlement Agreement, the promissory note between the Company and Aventisub LLC, a Sanofi affiliate, was terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $72.0 million. Sanofi also agreed to purchase $10.2 million of insulin from the Company in December 2016 under an existing insulin put option as well as make a cash payment of $30.6 million to the Company in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option, without the Company being required to deliver any insulin for such payment. The Company was also relieved of its obligation to pay Sanofi $0.5 million in previously uncharged costs pursuant to the Sanofi License Agreement. The Company and Sanofi also agreed to a general release of potential claims against each other. The settlement was accounted for in the year ended December 31, 2016, except for a $30.6 million cash payment received under the insulin put option agreement which reduced the receivable from Sanofi in the first quarter of 2017.

Sale of Intellectual Property

Sale of Intellectual Property	12 Months Ended
	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Sale of Intellectual Property	9. Sale of Intellectual Property On entered agreement paid one-time payment

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	10. Fair Value of Financial Instruments The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The carrying amounts reported in the accompanying consolidated financial statements for cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities (excluding the milestone rights liability) approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, note payable to principal stockholder (also referred to as The Mann Group Loan Arrangement), senior convertible notes, the facility financing obligation, the milestone rights liability and the warrant liability are disclosed in Note 10 – Fair Value of Financial Instruments. The fair value of the cash equivalents, note payable to principal stockholder, senior convertible notes, the Facility Financing Obligation (as defined below), the Milestone Rights (as defined below) and warrant liability are discussed below. Cash Equivalents — Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash. As of December 31, 2017 and 2016, the Company held $41.0 million and $20.5 million, respectively, of cash equivalents, comprised of money market funds. The fair value of these money market funds was determined by using quoted prices for identical investments in an active market (Level 1 in the fair value hierarchy). Note Payable to Principal Stockholder — The fair value of the note payable to the Company’s principal stockholder cannot be reasonably estimated as the Company would not be able to obtain a similar credit arrangement in the current economic environment. Therefore, the fair value is based upon carrying value. Financial Liabilities — The following tables set forth the fair value of the Company’s financial instruments (in millions): As of December 31, 2017 Fair Value Measurements Using Carrying Amount Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Financial liabilities: Senior convertible notes (2021 notes) $ 24.4 $ — $ — $ 19.8 $ 19.8 Facility financing obligation 52.7 — — 54.6 54.6 Milestone rights 8.9 — — 19.1 19.1 Total financial liabilities $ 86.0 $ — $ — $ 93.5 $ 93.5 As of December 31, 2016 Fair Value Measurements Using Carrying Value Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Financial liabilities: Senior convertible notes (2018 notes) $ 27.6 $ — $ — $ 22.9 $ 22.9 Facility financing obligation 71.3 — — 74.5 74.5 Milestone rights 8.9 — — 18.4 18.4 Warrant liability (at recurring fair value) 7.4 — — 7.4 7.4 Total financial liabilities $ 115.2 $ — $ — $ 123.2 $ 123.2 The following table provides a roll forward of the fair values of financial assets and liabilities that are carried at fair value (in millions): Warrants Assets Held for Sale Fair value, January 1, 2016 $ — $ — Additions 12.8 17.3 Changes in fair value (5.4 ) (0.6 ) Payments — — Fair value, December 31, 2016 $ 7.4 $ 16.7 Additions — — Changes in fair value (5.5 ) — Settlement through exchange of common shares (1.9 ) Payments — (16.7 ) Fair value, December 31, 2017 $ — $ — Senior Convertible Notes — The estimated fair value of the 2021 notes was calculated based on model-derived valuations whose inputs were observable, such as the Company’s stock price and yields on U.S. Treasury notes and actively traded bonds, and non-observable, such as the Company’s longer-term historical volatility, and estimated yields implied from any available market trades of the Company’s issued debt instruments. As there was no current active and observable market for the 2021 notes, the Company determined the estimated fair value using a convertible bond valuation model within a lattice framework. The convertible bond valuation model combined expected cash flows based on terms of the notes with market-based assumptions regarding risk-free rate, risk-adjusted yields (20%), stock price volatility (102%) and recent price quotes and trading information regarding Company issued debt instruments and shares of common stock into which the notes are convertible (Level 3 in the fair value hierarchy). Facility Financing Obligation — As discussed in Note 7 — Borrowings, the Company issued 2019 notes and subsequently issued Tranche B notes (the “Facility Financing Obligation”) in connection with the Facility Agreement. As there is no current observable market for the Facility Financing Obligation, the Company determined the estimated fair value using a bond valuation model based on a discounted cash flow methodology. The bond valuation model combined expected cash flows associated with principal repayment and interest based on the contractual terms of the debt agreement discounted to present value using a selected market discount rate. On December 31, 2017, the market discount rate was 12-13% for the principal for the facility financing obligation. Under the terms of the Facility Agreement, the Company is restricted from distributing any of its assets or declaring and distributing a dividend to its stockholders. Milestone Rights Liability — In addition to the Facility Financing Obligation, the Company also issued the Milestone Rights. These rights are not reflected in the Facility Financing Obligation. The estimated fair value of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones, discounted to present value using a selected market discount rate (Level 3 in the fair value hierarchy). The expected timing and probability of achieving the milestones, starting in 2014, was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate (14%) was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. As of December 31, 2017, the carrying value of the milestone rights liability was $8.9 million and the fair value was estimated at $19.1 million. The fair value measurement of the liability is sensitive to the discount rate and the timing and probability of making milestone payments. If the achievement of each of the milestones which require payments were to be six months later than in the current forecast, the fair value of the liability would decrease by 4%. If the probabilities of meeting the $50 to $200 million milestones were to decrease by 5% or 10%, the fair value of the liability would decrease by 14% and 28%, respectively. Over the long term, these inputs are interrelated because if the Company’s performance improves, the timing of meeting the milestones would likely be earlier, the probability of making payments on the milestones would likely be higher and the discount rate would likely decrease, all of which would increase the fair value of the liability. The inverse is also true. Warrant Liability — Warrant liabilities were measured at fair value using a Monte Carlo pricing valuation model. The assumptions used in the valuation model for the common stock warrant liabilities were: (a) a risk-free interest rate based on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the remaining contractual term of the warrants; (b) an assumed dividend yield of zero percent based on the Company’s expectation that it will pay no dividends in the foreseeable future; (c) an expected term based on the remaining contractual term of the warrants; (d) an expected volatility based upon the Company’s historical volatility over the remaining contractual term of the warrants; and (e) probability of a dilutive financing that may trigger a price protection clause. The significant unobservable input used in measuring the fair value of the common stock warrant liabilities is the expected volatility. Significant increases in volatility would result in a higher fair value measurement (Level 3 in the fair value hierarchy). Assets and Liabilities Measured at Fair Value on a Non-recurring Basis – Our assessment of the real property includes Level 3 inputs, and was based on a combination of the income, market and cost approaches and the market approach was used for machinery and equipment which required Level 3 inputs. Embedded Derivatives — The Company identified and evaluated a number of embedded features in the notes issued under the Facility Agreement to determine if they represented embedded derivatives that are required to be separated from the notes and accounted for as freestanding instruments. The Company analyzed the Tranche B notes and identified embedded derivatives, which required separate accounting. However, all of the embedded derivatives were determined to have a value at December 31, 2017 and 2016.

Common and Preferred Stock

Common and Preferred Stock	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Common and Preferred Stock	11. Common and Preferred Stock On December 13, 2017, the Company approved a proposal to amend the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 140,000,000 to 280,000,000 shares. The Company is authorized to issue 280,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of December 31, 2017 and 2016, 119,053,414 and 95,680,831 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. In November 2017, the Company sold an aggregate of 173,327 shares of the Company’s common stock at a purchase price of $3.15 per share pursuant to the Company’s At Market Issuance Sales Agreement with FBR Capital Markets & Co. The aggregate gross proceeds from the sales were approximately $0.5 million. On October 10, 2017, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors and a charitable foundation (collectively, the “Purchasers”). Pursuant to the terms of the Purchase Agreements, the Company sold to the Purchasers in a registered offering an aggregate of 10,166,600 shares of the Company’s common stock at a purchase price of $6.00 per share. Included in this offering was 166,600 shares issued to a charitable foundation associated with the Chairman of the Company’s board of directors. The net proceeds to the Company from the offering were approximately $57.7 million, after deducting placement agent fees equal to 5.0% of the aggregate gross proceeds from the offering (except for the proceeds received from the sale of 166,600 shares issued to the charitable foundation) and offering expenses payable by the Company . The offering closed on October 13, 2017. On March 1, 2017, the Company effected a 1-for-5 reverse stock split of the Company’s outstanding common stock. As a result, prior to March 1, 2017, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value. See Note 1 — Description of Business. On November 9, 2015, the Company entered into a series of stock purchase agreements to sell up to an aggregate of 10,000,000 shares of its common stock in a registered direct offering to selected investment funds in Israel that hold securities included within certain stock indexes of the Tel Aviv Stock Exchange (the “TASE”). Pursuant to the agreements, the shares of common stock were sold at a price per share equal to 97% of the closing price of the Company’s common stock on the TASE on November 12, 2015. During November 2015, the Company sold 2,770,487 shares of common stock for an aggregate price of approximately $34,710,000, or $13.05 per share, which is net of $1,432,000 of issuance costs. The Company engaged Sunrise Securities Corporation as its exclusive placement agent in connection with the offering of the 10,000,000 shares. In connection with the services provided, the Company issued to Sunrise Securities Corporation, or its designee, restricted warrants to purchase a number of shares of the Company’s common stock in an aggregate equal to 1.15% of the aggregate shares sold in the offering, which totaled approximately 32,000 shares on November 16, 2015. The warrants are exercisable for a five year period at an exercise price of $13.05, the price paid per share in connection with the offering. The Company had an obligation to register the common stock that may be issued pursuant to the exercise of the warrants, which resulted in their initial classification as liability and were deemed immaterial. On December 15, 2015 the warrants were reclassified to equity as the Company registered the common stock pursuant to a registration statement and continue to be classified in equity as of December 31, 2017. The Company’s stock was delisted from the TASE in November of 2017. During 2014, the Company loaned to Bank of America 1,800,000 shares of common stock under a share lending agreement in connection with the offering of the $100.0 million aggregate principal amount of the 2015 notes. Bank of America was obligated to return the borrowed shares (or, in certain circumstances, the cash value thereof) to the Company on or about the 45th business day following the date as of which the entire principal amount of the 2015 notes ceases to be outstanding, subject to extension or acceleration in certain circumstances or early termination at Bank of America’s option. On October 23, 2015, the 1,800,000 shares of common stock loaned to Bank of America were returned, as the Company settled all payments and deliveries in respect of such convertible notes on August 17, 2015. The Company did not receive any proceeds from the sale of the borrowed shares by Bank of America, but the Company did receive a nominal lending fee of $0.05 per share from Bank of America for the use of borrowed shares. For the year ended December 31, 2015, the Company received $10.1 million in proceeds from the exercise of the February 2012 public offering warrants. There were no warrant exercises during the year ended December 31, 2016 and any unexercised February 2012 public offering warrants expired on February 8, 2016.

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Net Income (Loss) Per Common Share	12. Net Income (Loss) per Common Share Basic net income (loss) per share excludes dilution for potentially dilutive securities and is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted net loss per share as they would be antidilutive. During 2015, 1,800,000 shares of the Company’s The following tables summarize the components of the basic and diluted net income (loss) per common share computations (in thousands, except per share amounts): Year Ended December 31, 2017 2016 2015 Basic EPS: Net (loss) income (numerator) $ (117,333 ) $ 125,664 $ (368,445 ) Weighted average common shares (denominator) 104,245 92,053 81,233 Net (loss) income per share $ (1.13 ) $ 1.37 $ (4.54 ) Diluted EPS: Net (loss) income (numerator) $ (117,333 ) $ 125,664 $ (368,445 ) Weighted average common shares 104,245 92,053 81,233 Effect of dilutive securities - common shares issuable — 32 — Adjusted weighted average common shares (denominator) 104,245 92,085 81,233 Net (loss) income per share $ (1.13 ) $ 1.36 $ (4.54 ) Common shares issuable represents incremental shares of common stock which consist of stock options, restricted stock units, warrants, and shares that could be issued upon conversion of the 2021 notes or the Facility Financing Obligation. Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares): December 31, 2017 2016 2015 Exercise of common stock options 7,089,440 5,530,256 3,955,845 Conversion of convertible notes into common stock 6,875,272 814,561 814,561 Employee stock purchase plan 136,660 43,672 33,986 Exercise of common stock warrants 31,856 9,740,597 814,919 Vesting of restricted stock units 1,135,216 702,867 360,924 15,268,444 16,831,953 5,980,235 Subsequent to December 31, 2017, the Company entered into an amendment to the Deerfield Facility Financing Obligation allowing additional principal amounts to be converted into equity. See Note 20 – Subsequent Events for further information.

Stock Award Plans

Stock Award Plans	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Award Plans	13. Stock Award Plans On May 23, 2013, the Company adopted the 2013 Equity Incentive Plan (the “2013 Plan”) as the successor to and continuation of the 2004 Equity Incentive Plan (the “2004 Plan”). The 2013 Plan consists of 4.3 million additional shares and the number of unallocated shares remaining available for grant for new awards under the 2004 Plan. The 2013 Plan provides for the granting of stock awards including stock options and restricted stock units, to employees, directors and consultants. No additional awards will be granted under the 2004 Plan or under the 2004 Non-Employee Directors’ Stock Option Plan (the “NED Plan”) as all future awards will be made out of the 2013 Plan. The following table summarizes information about the Company’s stock-based award plans as of December 31, 2017: Outstanding Options Outstanding Restricted Stock Units Shares Available for Future Issuance 2004 Equity Incentive Plan 1,231,740 — — 2013 Equity Incentive Plan 5,795,035 1,135,216 1,509,343 2004 Non-Employee Directors’ Stock Option Plan 62,665 — — Total 7,089,440 1,135,216 1,509,343 In March 2004, the Company’s board of directors approved the Employee Stock Purchase Plan (“ESPP”), which became effective upon the closing of the Company’s initial public offering. Initially, the aggregate number of shares that could be sold under the ESPP was 400,000 shares of common stock. On January 1 of each year, for a period of ten years beginning January 1, 2005, the share reserve automatically increased by the lesser of: 140,000 shares, 1% of the total number of shares of common stock outstanding on that date, or an amount as may be determined by the board of directors. However, under no event can the annual increase cause the total number of shares reserved under the ESPP to exceed 10% of the total number of shares of capital stock outstanding on December 31 of the prior year. As of December 31, 2017, 246,205 shares were available for issuance under the ESPP. For the years ended December 31, 2017, 2016 and 2015, the Company sold 199,578, 104,758 and 64,245 shares, respectively, of its common stock to employees participating in the ESPP. The ESPP purchase of 136,660 shares for the year ended December 31, 2017 was initiated prior to year-end but did not settle until January 3, 2018. As a result, the shares sold are reflected in the ESPP share reserves but are excluded from common stock outstanding as of December 31, 2017. The Company’s board of directors determines eligibility, vesting schedules and criteria and exercise prices for stock awards granted under the 2013 Plan. Options and restricted stock unit awards under the 2013 Plan expire not more than ten years from the date of the grant and are exercisable upon vesting. Stock options that vest over time generally vest over four years. Current time-based vesting stock option grants vest and become exercisable at the rate of 25% after one year and ratably on a monthly basis over a period of 36 months thereafter. Restricted stock units with time-based vesting generally vest at a rate of 25% per year over four years with consideration satisfied by service to the Company. The Company also issues stock awards with performance conditions. Share-based payment transactions are recognized as compensation cost based on the fair value of the instrument on the date of grant. The Company accounts for non-employee stock-based compensation expense based on the estimated fair value of the options, which is determined using the Black-Scholes option valuation model and amortizes such expense on a straight-line basis over the service period for time-based awards and over the expected dates of achievement for performance-based awards. These awards are subject to re-measurement until service is complete. As of December 31, 2017, there were options to purchase 23,047 shares of common stock outstanding to consultants. During the years ended December 31, 2017, 2016 and 2015, the Company recorded stock-based compensation expense of $4.8 million, $5.1 million and $8.7 million, respectively. Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is as follows (in thousands): Year Ended December 31, 2017 2016 2015 Employee-related $ 4,847 $ 5,135 $ 8,407 Consultant-related — — 318 Total $ 4,847 $ 5,135 $ 8,725 Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is included in the following categories (in thousands): Year Ended December 31, 2017 2016 2015 Cost of goods sold $ 460 $ 695 $ — Research and development 1,010 1,309 3,029 Selling, general and administrative 3,377 3,131 5,696 Total $ 4,847 $ 5,135 $ 8,725 The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options. The expected term of an option granted is based on combining historical exercise data with expected weighted time outstanding. Expected weighted time outstanding is calculated by assuming the settlement of outstanding awards is at the midpoint between the remaining weighted average vesting date and the expiration date. The expected volatility assumption is based on an assessment of the historical volatility, with consideration of implied volatility, derived from an analysis of historical trade activity. The Company has selected risk-free interest rates based on U.S. Treasury securities with an equivalent expected term in effect on the date the options were granted. Additionally, the Company uses historical data and management judgment to estimate stock option exercise behavior and employee turnover rates to estimate the number of stock option awards that will eventually vest. The Company calculated the fair value of employee stock options granted during the years ended December 31, 2017, 2016 and 2015 using the following assumptions: Year Ended December 31, 2017 2016 2015 Risk-free interest rate 1.83% — 2.13% 1.18% — 1.80% 1.61% —1.86% Expected lives 5.41 — 5.78 years 5.13 — 5.82 years 5.79 — 5.86 years Volatility 83.32% — 90.39% 77.57% — 82.75% 69.76% — 71.84% Dividends — — — The following table summarizes information about stock options outstanding: Number of Shares Weighted Average Exercise Price per Share Aggregate Intrinsic Value ($000) Outstanding at January 1, 2017 5,530,256 $ 16.10 Granted 3,335,385 1.60 Exercised (5,300 ) 4.55 Forfeited (598,204 ) 3.17 Expired (1,172,697 ) 22.21 Outstanding at December 31, 2017 7,089,440 $ 9.33 $ 2,484 Vested and expected to vest at December 31, 2017 6,735,675 $ 9.70 $ 2,262 Exercisable at December 31, 2017 2,813,227 $ 19.52 $ 61 The weighted average grant date fair value of the stock options granted during the years ended December 31, 2017, 2016 and 2015 was $1.19, $3.05 and $12.80 per option, respectively. The total intrinsic value of options exercised during the year ended December 31, 2017 was de minimis. The total intrinsic value of options exercised during the years ended December 31, 2016 and 2015 was $0.1 million and $6.2 million, respectively. Intrinsic value is measured using the fair market value at the date of exercise for options exercised or at December 31 for outstanding options, less the applicable exercise price. Cash received from the exercise of options during the years ended December 31, 2017, 2016 and 2015 was approximately $0.02 million, $0.5 million and $3.3 million, respectively. The weighted-average remaining contractual terms for options outstanding, vested and expected to vest and exercisable at December 31, 2017 was 6.87 years, 6.75 years and 3.57 years, respectively. A summary of restricted stock unit activity for the year ended December 31, 2017 is presented below: Number of Shares Weighted Average Grant Date Fair Value per Share Outstanding at January 1, 2017 737,966 $ 8.40 Granted 669,091 1.36 Vested (192,361 ) 10.02 Forfeited (79,480 ) 5.89 Outstanding at December 31, 2017 1,135,216 $ 4.08 The total restricted stock units expected to vest as of December 31, 2017 was 939,240 with a weighted average grant date fair value of $4.28 per share. The total intrinsic value of restricted stock units expected to vest as of December 31, 2017 was $2.2 million. Intrinsic value of restricted stock units expected to vest is measured using the closing share price at December 31, 2017. Total intrinsic value of restricted stock units vested during the years ended December 31, 2017, 2016 and 2015 was $0.4 million, $0.6 million and $5.2 million, respectively. Intrinsic value of restricted stock units vested is measured using the closing share price on the day prior to the vest date. The total grant date fair value of restricted stock units vested during the years ended December 31, 2017, 2016 and 2015 was $1.9 million, $2.6 million and $5.5 million, respectively. As of December 31, 2017, there was $2.9 million and $3.2 million of unrecognized compensation expense related to options and restricted stock units with performance conditions, respectively, which is expected to be recognized over the weighted average vesting period of 2.3 years. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and uses that information to estimate the date at which those performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. As of December 31, 2017 and 2016, the Company recognized $0.9 million and $0.3 million of compensation costs related to the performance-based stock options, respectively. As of December 31, 2017, there was $3.5 million of unrecognized compensation costs related to performance-based stock options subject to performance conditions. During the year ended December 31, 2015, there was $1.6 million of stock compensation expense related to certain executives who entered into severance agreements which resulted in a modification to the terms of their awards. The severance agreements generally allowed for the separated executives to continue to vest under their original award terms for a stated period of time without providing substantive services. There were no modifications in 2017 or 2016.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. The Company has not recorded any liability for these indemnities in the accompanying consolidated balance sheets. However, the Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date. Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. As of December 31, 2017, the Company believes that the final disposition of such matters will not have a material adverse effect on the financial position, results of operations or cash flows of the Company and no accrual has been recorded. The Company maintains liability insurance coverage to protect the Company’s assets from losses arising out of or involving activities associated with ongoing and normal business operations. The Company records a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company’s policy is to accrue for legal expenses in connection with legal proceedings and claims as they are incurred. Following the public announcement of Sanofi’s election to terminate the Sanofi License Agreement and the subsequent decline in the Company’s stock price, two motions were submitted to the district court at Tel Aviv, Economic Department for the certification of a class action against the Company and certain of its officers and directors. In general, the complaints alleged that the Company and certain of its officers and directors violated Israeli and U.S. securities laws by making materially false and misleading statements regarding the prospects for Afrezza, thereby artificially inflating the price of its common stock. The plaintiffs are seeking monetary damages. In November 2016, the district court dismissed one of the actions without prejudice. In the remaining action, the district court recently ruled that U.S. law will apply to this case. The Company is in the process of preparing a response to the plaintiff’s motion to certify the case as a class action. The Company will vigorously defend against the claims advanced. Contingencies — In connection with the Facility Agreement, on July 1, 2013, the Company also entered into a the Milestone Agreement with the Milestone Purchasers, pursuant to which the Company sold the Milestone Purchasers the Milestone Rights to receive payments up to $90.0 million upon the occurrence of specified strategic and sales milestones, including the first commercial sale of an Afrezza product in the United States and the achievement of specified net sales figures (see Note 7 – Borrowings). Commitments — On July 31, 2014, the Company entered into a supply agreement (the “Insulin Supply Agreement”) with Amphastar France Pharmaceuticals S.A.S., a French corporation (“Amphastar”), pursuant to which Amphastar manufactures for and supplies to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar is responsible for manufacturing the insulin in accordance with the Company’s specifications and agreed-upon quality standards. On November 9, 2016, the supply agreement with Amphastar was amended to extend the term over which the Company is required to purchase insulin, without reducing the total amount of insulin to be purchased. Under the amendment, annual minimum quantities of insulin to be purchased for calendar years 2018 through 2023 total an aggregate purchase price of €90.3 million at December 31, 2017. The Insulin Supply Agreement specifies that Amphastar will be deemed to have satisfied its obligations with respect to quantity, if the actual quantity supplied is within plus or minus ten percent (+/- 10%) of the quantity set forth in the applicable purchase order. In addition, the aggregate cancellation fees that the Company would incur in the event that certain insulin quantities are not purchased was lowered from $5.3 million for the period October 1, 2016 through 2018 to $3.4 million over the same period. The annual purchase requirements under the contract are as follows: 2018 € 8.9 million 2019 € 11.6 million 2020 € 15.5 million 2021 € 15.5 million 2022 € 19.4 million 2023 € 19.4 million The Company took delivery of the required amount of insulin under the contract in 2017 but was only obligated to pay for half prior to December 31, 2017. Accordingly, approximately $1.6 million is included in accounts payable at December 31, 2017 related to the 2017 purchase requirement. The Company also paid cancellation fees of $1.4 million in 2017, which were previously included in the recognized loss on purchase commitments. Unless terminated earlier, the term of the Insulin Supply Agreement with Amphastar expires on December 31, 2023 and can be renewed for additional, successive two year terms upon 12 months’ written notice given prior to the end of the initial term or any additional two year term. The Company and Amphastar each have normal and customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days’ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination. At December 31, 2017, the Company has other firm commitments with suppliers for an aggregate of $0.4 million. Office Lease — On May 5, 2017, the Company executed an office lease with Russell Ranch Road II LLC for the Company’s corporate headquarters in Westlake Village, California. The office lease commenced in August 2017. The lease requires monthly payments of $40,951, increased by 3% annually, plus the estimated cost of maintaining the property by the landlord with a five month concession from October 2017 through February 2018. The lease expires January 2023 and provides the Company with a five year renewal option. On November 29, 2017, the Company executed an office lease with Russell Ranch Road II LLC to expand the office space for the Company’s corporate headquarters in Westlake Village, California. The office lease will commence in October 2018. The lease requires monthly payments of $35,969, increased by 3% annually, plus the estimated cost of maintaining the property by the landlord. In addition, the Company will be entitled to reimbursement from the landlord of up to $56,325 for tenant improvements. The lease expires January 2023 and provides the Company with a five year renewal option. Rent expense under all operating leases including office space and equipment was approximately $0.4 million for the year ended December 31, 2017, 2016 and 2015, respectively. Future minimum lease payments are as follows: 2018 $ 522,000 2019 947,000 2020 976,000 2021 1,005,000 2022 1,035,000 Thereafter 88,000 $ 4,573,000

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	15. Employee Benefit Plans The Company administers a 401(k) savings retirement plan (the “MannKind Retirement Plan”) for its employees. For the years ended December 31, 2017, 2016 and 2015, the Company contributed $0.4 million, $0.4 million and $0.6 million, respectively, to the MannKind Retirement Plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes Loss from continuing operations before provision for income tax for the Company’s domestic and international operations was as follows (in thousands): December 31, 2017 2016 2015 US $ (113,679 ) $ 129,361 $ (358,047 ) Foreign (3,603 ) (3,697 ) (10,398 ) Loss before provision for income taxes $ (117,282 ) $ 125,664 $ (368,445 ) At December 31, 2017, the Company has concluded that it is more likely than not that the Company may not realize the benefit of its deferred tax assets due to its history of losses. The provision for income taxes for the year ended December 31, 2017 was $0.05 million, and there was no provision for income taxes for the years ended December 31, 2016 and 2015, respectively because the Company had incurred operating losses since inception. Accordingly, the net deferred tax assets have been fully reserved. The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2017 2016 2015 Current U.S. federal $ 51 $ — $ — U.S. state — — — Non-U.S. — — — Total current 51 — — Deferred U.S. federal 244,801 (43,814 ) 109,512 U.S. state 15,398 (4,311 ) (29,394 ) Non-U.S. — — — Total deferred 260,199 (48,125 ) 80,118 Valuation allowance (260,199 ) 48,125 (80,118 ) Total $ 51 $ — $ — Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. A valuation allowance is established when uncertainty exists as to whether all or a portion of the net deferred tax assets will be realized. Components of the net deferred tax assets as of December 31, 2017 and 2016, are as follows (in thousands): December 31, 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 507,235 $ 712,124 Research and development credits 83,461 77,998 Capitalized research 1,016 5,117 Milestone Rights 1,908 3,242 Accrued expenses 211 440 Loss on purchase commitment 23,654 36,775 Non-qualified stock option expense 7,004 17,331 Capitalized patent costs 5,194 8,781 Other 795 7,380 Depreciation 23,820 45,310 Total net deferred tax assets 654,298 914,498 Valuation allowance (654,298 ) (914,498 ) Net deferred tax assets $ — $ — The Company’s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December 31, 2017, 2016 and 2015: December 31, 2017 2016 2015 Federal tax benefit rate 35.0 % 35.0 % 35.0 % Permanent items 6.2 (1.9 ) — Intercompany transfer of intellectual property — 0.9 (1.0 ) 2017 tax law changes (265.0 ) — — Stock based compensation (5.0 ) — — Tax attribute expirations (2.8 ) — — Valuation allowance 231.6 (34.0 ) (34.0 ) Effective income tax rate — % — % — % As of December 31, 2017 and 2016, management assessed the realizability of deferred tax assets. Management evaluated the need for an amount of any valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, Income Taxes In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that “a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.” Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2017. Accordingly, a valuation allowance of $654.3 million has been recorded to offset this deferred tax asset. During the years ended December 31, 2017 and 2016, the change in the valuation allowance was $(260.2) million and $(48.1) million, respectively. At December 31, 2017, the Company had federal and state net operating loss carryforwards of approximately $2.0 billion and $2.2 billion available, respectively, to reduce future taxable income. These losses are available to reduce taxable income and have started expiring, starting in the current year through various future dates for both federal and state purposes. As a result of the Company’s initial public offering, an ownership change within the meaning of Internal Revenue Code Section 382 occurred in August 2004. As a result, federal net operating loss and credit carry forwards of approximately $216.0 million are subject to an annual use limitation of approximately $13.0 million. The annual limitation is cumulative and therefore, if not fully utilized in a year can be utilized in future years in addition to the Section 382 limitation for those years. The federal net operating losses generated subsequent to the Company’s initial public offering in August 2004 are currently not subject to any such limitation as there have been no ownership changes since August 2004 within the meaning of Internal Revenue Code Section 382. At December 31, 2017, the Company had research and development credits of $55.1 million and $28.4 million for federal and state purposes, respectively. The federal credits begin to expire in 2024, and the state credits may be carried forward indefinitely. The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. In the normal course of business the Company is subject to examination by taxing authorities throughout the country. These audits could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with federal, state and local laws. The Company’s tax years since 2012 remain subject to examination by federal, state and foreign tax authorities. We adopted ASU 2016-09 in the first quarter of 2017. Under the new guidance companies will no longer record excess tax benefits and certain tax deficiencies related to share-based payments to employees in additional paid-in capital (APIC). Instead, the Company will recognize all income tax effects of awards in our income statement when awards vest or are settled. All excess tax benefits not previously recognized were to be recorded to retained earnings as a cumulative effect adjustment upon adoption. Upon adoption, no adjustment to retained earnings was necessary due to the Company’s valuation allowance position. Approximately $10.8 million attributable to excess tax benefits on stock compensation that had not been previously recognized were added to the Net Operating Loss with a corresponding increase to the valuation allowance. At December 31, 2017 and 2016, the Company has not recognized a liability for unrecognized tax benefits If any were recognized, it would affect the Company’s effective tax rate. The Company does not expect its unrecognized tax benefits to change. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. During the year ended December 31, 2017, the interest and penalties recognized were not material. During the years ended December 31, 2016 and 2015 the Company recognized and accrued an insignificant amount of interest or penalties related to unrecognized tax benefits. The Company considers its undistributed earnings of foreign subsidiaries to be permanently reinvested in foreign operations and has not provided for U.S. income taxes on such earnings. As of December 31, 2017 the Company had no undistributed earnings from its foreign subsidiaries. On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code of 1986, as amended. The changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017, and expanded limits on employee remuneration. The Company has calculated its best estimate of the impact of the Act in its year end income tax provision in accordance with its understanding of the Act and guidance available as of the date of this filing, and as a result, the Company recorded no additional income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted. The provisional amount related to the remeasurement of certain deferred tax assets and liabilities is based on the rates at which they are expected to reverse in the future. The impact of this Act was a decrease of deferred tax assets approximately $301 million, offset by a decrease in valuation allowance of $301 million, resulting in no additional income tax expense or benefit. No provisional amount was recorded related to the one-time transition tax on the mandatory deemed repatriation of foreign earnings. Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. In accordance with SAB 118, the Company has determined that the provisional amounts recorded are a reasonable estimate at December 31, 2017. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 during which the analysis is complete.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Warrants	17. Warrants In May 2016, the Company sold in a registered offering an aggregate of 9,708,737 shares of common stock together with A Warrants exercisable for up to an aggregate of 7,281,553 shares of common stock and B Warrants exercisable for up to an aggregate of 2,427,184 shares of common stock with a total fair value of $44.7 million. Each of the warrants had an exercise price of $7.50 per share. The A Warrants became exercisable upon issuance and expired two years thereafter. The B Warrants became exercisable beginning in May 2017 and expired 30 months after the date of issuance. The shares of common stock and the warrants are immediately separable and issued separately. The Company determined that the A Warrants required liability classification primarily due to a price-protection clause that applies in the event of certain dilutive financings. The fair value of the A Warrants was recorded as a warrant liability in the consolidated balance sheet at issuance and was adjusted to fair value at each reporting period until exercise or expiration. The Company determined that the B Warrants met the criteria for equity classification and accounted for such warrants in additional paid in capital. On September 29, 2017 the Company and four holders of 9.7 million A and B Warrants entered into separate, privately-negotiated exchange agreements, pursuant to which the Company agreed to issue to such holders an aggregate of 1,292,510 shares of the Company’s common stock (to be delivered on October 3, 2017) in exchange for such warrants. The warrant liability associated with the exchanged warrants was adjusted to fair value and $1.9 million, the fair value of the remaining obligation was reclassified into equity as of September 29, 2017. In addition, as of December 31, 2017, warrants to acquire approximately 32,000 shares of common stock were outstanding. See Note 11 – Common and Preferred Stock, for additional information.

Restructuring Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Restructuring Charges	18. Restructuring Charges As of December 31, 2017 and 2016, the Company had a remaining restructuring liability of $0.4 million and $1.4 million, respectively, which is recorded in accrued expenses and other current liabilities in the consolidated balance sheets. The Company expects to substantially pay out the remainder of this obligation by end of first quarter of 2018. A reconciliation of beginning and ending liability balances for the restructuring charges is as follows (in thousands): Description 2016 Restructuring 2015 Restructuring Total Accrual — January 1, 2016 $ — $ 3,028 $ 3,028 Costs incurred and charged to expense 1,475 560 2,035 Costs paid or settled (1,266 ) (2,421 ) (3,687 ) Accrual — December 31, 2016 209 1,167 1,376 Costs incurred and charged to expense — — — Costs paid or settled (209 ) (805 ) (1,014 ) Accrual — December 31, 2017 $ — $ 362 $ 362

Selected quarterly financial da

Selected quarterly financial data (unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Selected quarterly financial data (unaudited)	19. Selected quarterly financial data (unaudited) Summarized quarterly financial data for the years ended December 31, 2017 and 2016, are set forth in the following tables: March 31 June 30 September 30 December 31 (In thousands, except per share data) 2017 Net revenues $ 3,009 $ 2,163 $ 2,043 $ 4,530 Net (loss) $ (16,324 ) $ (35,339 ) $ (32,886 ) (32,784 ) Net (loss) per share — basic $ (0.17 ) $ (0.35 ) $ (0.31 ) $ (0.28 ) Net (loss) per share — diluted $ (0.17 ) $ (0.35 ) $ (0.31 ) $ (0.28 ) Weighted average common shares used to compute basic net (loss) per share 95,744 99,864 104,703 116,451 Weighted average common shares used to compute diluted net (loss) per share 95,744 99,864 104,703 116,451 2016 Net revenues $ — $ — $ 162,354 $ 12,404 Net income (loss) $ (24,873 ) $ (29,959 ) $ 126,520 $ 53,976 Net income (loss) per share — basic $ (0.29 ) $ (0.33 ) $ 1.32 $ 0.56 Net income (loss) per share — diluted (0.29 ) $ (0.33 ) 1.31 0.56 Weighted average common shares used to compute basic net income (loss) per share 85,771 91,061 95,627 95,676 Weighted average common shares used to compute diluted net income (loss) per share 85,771 91,061 96,548 96,510 In the third quarter of 2016, the Company recognized net revenue-collaboration of $161.8 million attributable to collaboration with Sanofi (See Note 8 — Collaboration Arrangements). In the fourth quarter of 2016, the Company recognized net revenue-collaboration of $10.2 million attributable to collaboration with Sanofi and $72.0 million gain on extinguishment of debt (See Note 8 — Collaboration Arrangements) In the fourth quarter of 2017, the Company recognized net revenue-commercial product sales of $1.2 million attributable to a change in estimate (See Note 1 – Description of Business)

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events Fifth Amendment to Facility Agreement and First Amendment to Escrow Agreement On January 15, 2018, the Company and MannKind LLC entered into a Fifth Amendment (the “Fifth Deerfield Amendment”) with Deerfield to the facility Agreement, pursuant to which the parties deferred the payment date for the $4.4 million remaining October 2017 Tranche 4 Principal Payment from January 15, 2018 to January 19, 2018. Concurrent with this amendment the Company and MannKind LLC entered into a First Amendment to Escrow Agreement to extend the escrow period to January 19, 2018 to align with the amended payment date under the Fifth Deerfield Amendment. Sixth Amendment to Facility Agreement and Second Amendment to Escrow Agreement On January 18, 2018, the Company and MannKind LLC entered into an Exchange and Sixth Amendment to Facility Agreement (the “Sixth Deerfield Amendment”) with Deerfield, pursuant to which, among other things, the Company agreed to issue to Deerfield an aggregate of 1,267,972 shares of its common stock, par value $0.01 per share (the “Exchange Shares”), in exchange for $3,157,251 of the 2019 Notes, an exchange rate of $2.49 per share. In addition, the parties deferred the payment date for the $1,250,000 remaining principal amount of the 2019 Notes (the “Remaining Payment”) from January 19, 2018 to May 6, 2018. The Company and Deerfield also amended the outstanding 2019 Notes and Tranche B notes to provide that Deerfield may, subject to the terms of the Sixth Deerfield Amendment, convert principal amounts of the 2019 notes and Tranche B notes from time to time into an aggregate of up to 10,000,000 shares of the Company’s common stock (excluding the Exchange Shares). The conversion price will be the greater of (i) the average of the volume weighted average price per share of the Company’s common stock for the three trading day period immediately preceding the date of any election by Deerfield to convert principal amounts of the 2019 notes and Tranche B notes and (ii) $2.75 per share, subject to adjustment under certain circumstances described in the 2019 notes and Tranche B notes. Any conversions of principal by Deerfield under the 2019 notes and Tranche B notes will be applied first to reduce the Remaining Payment, and thereafter to reduce other principal payments due under the 2019 notes and Tranche B notes. In connection with the Sixth Deerfield Amendment, the Company also entered into a Second Amendment to Escrow Agreement, dated January 18, 2018, with Deerfield and US Bank, pursuant to which the parties extended the period of the escrow established thereunder to May 6, 2018, corresponding to the extended payment date under the Facility Agreement.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Business	Business — MannKind Corporation and Subsidiaries (the “Company”) is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. The Company’s only approved product, Afrezza (insulin human) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the “FDA”) in June of 2014 to improve glycemic control in adults with diabetes. Afrezza became available by prescription in U.S. retail pharmacies in February 2015. Pursuant to a license and collaboration agreement (the “Sanofi License Agreement”) between the Company and Sanofi-Aventis U.S. LLC (“Sanofi”). Sanofi was responsible for global commercial, regulatory and development activities associated with Afrezza from August 2014 to April 2016. After a transition period during which Sanofi continued to fulfill orders for Afrezza, the Company assumed responsibility for worldwide development and commercialization of Afrezza and the Company began distributing MannKind-branded Afrezza to wholesalers in July 2016. During the second half of 2016, the Company utilized a contract sales organization to promote Afrezza while the Company focused its internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, the Company recruited its own specialty sales force to promote Afrezza to endocrinologists and certain high-prescribing primary care physicians. The Company’s current strategy for future commercialization of Afrezza outside of the United States, subject to receipt of the necessary foreign regulatory approvals, is to seek and establish regional partnerships in foreign jurisdictions where there are appropriate commercial opportunities.
Basis of Presentation	Basis of Presentation - The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is not currently profitable and has rarely generated positive net cash flow from operations. As of December 31, 2017, the Company had an accumulated deficit of $(2.9) billion. At December 31, 2017, the Company’s capital resources consisted of cash and cash equivalents of $43.9 million. The Company expects to continue to incur significant expenditures to support commercial manufacturing, sales and marketing of Afrezza and the development of product candidates in the Company’s pipeline. The facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (“Deerfield Private Design Fund”) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) that resulted in the issuance of 9.75% Senior Convertible Notes due 2019 (“2019 notes”) and the First Amendment to Facility Agreement and Registration Rights Agreement (the “First Amendment”) that resulted in the issuance of an additional tranche of 8.75% Senior Convertible Notes due 2019 (“Tranche B notes”) (see Note 7 — Borrowings) requires the Company to maintain at least $25.0 million in cash and cash equivalents or available borrowings under the loan arrangement, dated as of October 2, 2007, between the Company and The Mann Group LLC (“The Mann Group”) (as amended, restated, or otherwise modified as of the date hereof, “The Mann Group Loan Arrangement”), as of the last day of each fiscal quarter. On June 29, 2017, the Company entered into an Exchange and Third Amendment to the Facility Agreement (the “Third Amendment”) with Deerfield which, among other things, amended such financial covenant to provide that, if certain conditions are met, then the obligation to maintain at least $25.0 million in cash as of the end of each quarter will be reduced to $10.0 million as of August 31, 2017, September 30, 2017, October 31, 2017 and December 31, 2017 if certain conditions were met (see Note 7 — Borrowings). We met the conditions at each of these month-ends. As of December 31, 2017, the Company has $157.8 million principal amount of outstanding borrowings. The Company has entered into certain transaction related to these borrowings during 2017 and 2018 that are more fully described in Note 6 - Related Party Agreements, Note 7 – Borrowings and Note 20 – Subsequent Events. The Company’s available cash and financing sources will not be sufficient to meet its current and anticipated cash requirements, accordingly, these factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The Company plans to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with another company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development and commercialization of Afrezza and other product candidates and to support its other ongoing activities. The Company cannot provide assurances that such additional capital will be available on acceptable terms or at all. Successful completion of these plans is dependent on factors outside of the Company’s control. As such, management cannot be certain that such plans will be effectively implemented within one year after the date that the financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Reverse Stock Split	Reverse Stock Split - On March 1, 2017, following stockholder approval, the Company’s board of directors approved a 1-for-5 reverse stock split of its outstanding common stock. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, prior to March 3, 2017, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
Correction of an Immaterial Error	Correction of an Immaterial Error — Subsequent to the issuance of the Company’s financial statements for the year ended December 31, 2016 on Form 10-K, the Company determined that the common stock par value as of December 31, 2016 should not have been retrospectively adjusted for the impact of the reverse stock split on March 3, 2017 as described above. Management evaluated the materiality of the errors from a quantitative and qualitative perspective and concluded that this adjustment was not material to the Company’s previously issued financial statements. The Company has elected to revise the historical consolidated financial information presented herein in the consolidated balance sheet and statements of stockholders’ deficit to reflect the correction of this error for the prior periods presented. Since the revisions were not material, no amendments to previously filed reports were required. The revisions had the effect of decreasing common stock and increasing additional paid in capital by $3.8 million, $3.4 million, and $3.2 million as of December 31, 2016 and 2015 and January 1, 2015, respectively. Each affected individual line item within the consolidated statements of stockholders’ deficit relating to issuances of common shares for any reason and the return of loaned common stock in the years ended December 31, 2016 and 2015 have likewise been revised to decrease the common stock and increase the additional paid in capital attributable to each such transaction.
Principles of Consolidation	Principles of Consolidation — The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.
Segment Information	Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America.
Revenue Recognition	Revenue Recognition — Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When the accounting requirements for revenue recognition are not met, the Company defers the recognition of revenue by recording deferred revenue on the consolidated balance sheets until such time that all criteria are met. To date, the Company has had revenue from commercial sales of Afrezza, collaborations, sale of intellectual property and bulk insulin sales, which are described more fully below.
Revenue Recognition - Net Revenue - Commercial Product Sales	Revenue Recognition – Net Revenue – Commercial Product Sales – The Company currently sells Afrezza through two channels: wholesale distributors and specialty pharmacies as further described below. The Company provides the right of return for unopened product for a period beginning six months prior to and ending twelve months after its expiration date. This right of return is provided to (1) the Company’s wholesale distributors and, through them, to its retail pharmacy customers, and (2) to its specialty pharmacies. Once the product has been prescribed and dispensed to the patient, any right of return ceases to exist. Sales of Afrezza through Wholesale Distributors - Between July 1, 2016 and December 15, 2016, the Company sold Afrezza to Integrated Commercialization Solutions Direct (“ICS”) and title and risk of loss transferred to ICS upon shipment. After December 15, 2016, ICS became a third party logistics provider and stopped taking title and risk of loss upon shipment of Afrezza to ICS. The Company sells Afrezza in the United States to wholesale pharmaceutical distributors through ICS, and ultimately to retail pharmacies, which are collectively referred to as “customers”. The current accounting guidance requires the Company to reliably estimate returns in order to recognize revenue upon shipment. While we can currently estimate returns within a range, it is not sufficiently precise to meet the current requirements. Accordingly, the Company defers recognition of revenue on Afrezza product shipments through wholesale distributors until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. Deferred revenue is presented net of deferred product sales discounts which are further described in Gross-to-net Adjustments Change in Estimate – In the fourth quarter of 2017, the Company obtained new and more comprehensive data regarding the inventory in the distribution channel. This data indicated that the amount of inventory in the distribution channel was less than previously estimated. Because the new data was more comprehensive than the data that was previously available to the Company, the Company adjusted the ending gross deferred revenue balance to match the new estimate. In addition to adjusting the gross deferred revenue balance, the Company adjusted the ending balances of deferred discounts and deferred cost of goods sold. The net effect of this change was an increase to net income of $1.2 million or $0.01 basic and diluted net income (loss) per share for the year ended December 31, 2017. Sales of Afrezza through Specialty Pharmacies - During the first quarter of 2017, the Company began selling Afrezza to a network of specialty pharmacies. Specialty pharmacies generally purchase product on demand. Title and risk of loss passes to the specialty pharmacies at shipment and our estimated returns are minimal. Therefore, the Company recognizes revenue for sales through specialty pharmacies at the time the product is shipped to the specialty pharmacies, net of as described below. For the year ended December 31, 2017, the net amount of revenue recognized from sales to specialty pharmacies was $0.5 million. For the years ended December 31, 2017 and 2016, Afrezza net revenue from commercial product sales consisted of $9.2 million and $1.9 million of net sales, respectively. As of December 31, 2017 and 2016, the ending balances for net deferred revenue, were $3.0 million and $3.4 million, on the Company’s consolidated balance sheets which are presented net of $1.5 million and $0.8 million in deferred gross-to-net adjustments, respectively. The December 31, 2016 deferred revenue balance includes $1.7 million of bulk insulin sales which is described more fully under the heading Revenue Recognition – Revenue – Other
Gross-to-net Adjustments	Gross-to-net Adjustments — Estimated gross-to-net adjustments for Afrezza include wholesaler distribution fees, prompt pay discounts, estimated rebates and chargebacks and patient discount and co-pay assistance programs, and are based on estimated amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of the Company’s agreements with its customers and the levels of inventory within the distribution and retail channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of gross revenue based on estimated utilization. If actual future results vary, the Company may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. The Company records product sales deductions in the consolidated statements of operations at the time product revenue is recognized. At December 31, 2017 and 2016, year to date total gross-to-net adjustments were approximately $ 3.4 million and $0.8 million, which represents 27% and 30% of gross revenue from product sales, respectively. Gross-to-net items that are unpaid at the end of each period are presented in discounts and allowances for commercial product sales in accrued expense and other current liabilities.
Wholesaler Distribution Fees	Wholesaler Distribution Fees — The Company pays distribution fees to certain wholesale distributors based on contractually determined rates. The Company accrues the distribution fees on shipment to the respective wholesale distributors and recognizes the distribution fees as a reduction of revenue in the same period the related revenue is recognized.
Prompt Pay Discounts	Prompt Pay Discounts — The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable and deferred revenue by the prompt pay discount amount (at the time of shipment to the wholesale distributor). The Company recognizes the cash discounts as a reduction of revenue in the same period the related revenue is recognized. Rebates and Chargebacks — Most of our rebates are contractual or legislatively mandated. Sales rebates include managed care, Medicare, Medicaid, and various other programs. The Company participates in federal and state government-managed Medicare and Medicaid rebate programs and, as such, is required to provide rebates under these programs. Chargebacks are discounts that occur when customers purchase directly from an intermediary wholesale purchaser. The Company accounts for these rebates and chargebacks by establishing an accrual based on contractual discount rates, expected utilization under each contract and an estimate of the amount of inventory in the distribution channel that will become subject to such rebates and chargebacks based on historical payor data provided by a third-party vendor along with additional data including forecasted participation rate. From that data, as well as input received from the commercial team, an estimated participation rate for each program is determined and applied at the rate for those sales. Any new information regarding changes in the programs’ regulations and guidelines or any changes in the Company’s
Patient Discount and Co-Pay Assistance Programs	Patient Discount and Co-Pay Assistance Programs — The Company offers discount card programs to patients for Afrezza in which patients receive discounts on their prescriptions or a reduction in their co-pay amounts that are reimbursed by the Company. The Company estimates the total amount that will be redeemed based on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.
Deferred costs	Deferred Costs from Commercial Product Sales — Deferred costs from commercial product sales represents the cost of product (including labor, overhead and shipping costs to third party logistics providers) shipped to wholesale distributors, but not dispensed by pharmacies to patients. If the Company estimates that inventory that has been shipped to wholesale distributors will be returned for credit because there is a risk of product expiry, deferred costs of commercial product sales is reduced and cost of goods sold is increased for the cost of such inventory.
Revenue Recognition- Net Revenue - Collaborations	Revenue Recognition — Net Revenue — Collaborations — The Company enters into collaborations under which we must perform certain obligations and receive periodic payments. The Company evaluates the collaborations under the multiple element revenue recognition accounting guidance. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered elements have stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit. The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. The terms of and the accounting for the Company’s collaborations are described more fully in Note 8 — Collaboration Arrangements.
Revenue Recognition — Revenue — Other	Revenue Recognition — Revenue — Other — In 2017, Revenue-other consists of $1.7 million of revenue from bulk insulin sales and $0.6 million related to the sale of intellectual property to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd (“Fosun”), which is accounted for under the multiple-deliverable revenue recognition guidance and more fully described in Note 9 – Sale of Intellectual Property. Revenue from bulk insulin sales are recognized after delivery and customer acceptance of the bulk insulin. When the accounting requirements for revenue recognition of bulk insulin sales are not met, the Company defers recognition of revenue until such time that all criteria are met. As of December 31, 2016 the ending balance in deferred revenue included amounts related to bulk insulin sales of approximately $1.7 million. There was no deferred revenue related to bulk insulin sales as of December 31, 2017.
Cost of Goods Sold	Cost of Goods Sold — Cost of goods sold includes the costs related to Afrezza product dispensed by pharmacies to patients as well as the following costs which are expensed as incurred rather than capitalized into inventory: excess capacity labor and overhead, the impact of the annual revaluation of inventory and deferred costs of commercial sales to standard costs, and write-offs of inventory and deferred costs of commercial sales.
Cash and Cash Equivalents	Cash and Cash Equivalents — The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash to be cash equivalents. As of December 31, 2017 and 2016, cash equivalents were comprised of money market accounts with maturities less than 90 days from the date of purchase.
Restricted Cash	Restricted Cash – The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. The Company presents amounts of restricted cash that will be available for use within twelve months of the reporting date as restricted cash in current assets. Restricted cash amounts that will not be available for use in the Company’s operations within twelve months of the reporting date are presented as restricted cash in long term assets.
Concentration of Credit Risk	Concentration of Credit Risk — Financial instruments which potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market accounts, which are regularly monitored by management.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. If the Company estimates that inventory that has been shipped to wholesale distributors will be returned for credit because there is a risk of product expiration, the Company reduces deferred revenue and increases the allowance for returns of such inventory. As of December 31, 2017 and 2016, the allowance for returns was de minimis. As of December 31, 2017 and 2016, there was no allowance for doubtful accounts. As of December 31, 2017 and 2016, the Company had three wholesale distributors representing approximately 93% and 95% of gross accounts receivable, respectively.
Inventories	Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company’s products based on management’s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as cost of goods sold. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand at December 31, 2017 and 2016. As a result of these assessments, the Company recorded a $3.0 million charge for the year ended December 31, 2017, to write-off inventory that may expire prior to sale. For the year ended December 31, 2016 there were no write-offs to inventory. For the year ended December 31, 2015, the Company recorded a charge of $39.3 million to record the inventory raw materials on hand at the lower of cost or net realizable value, inventory expiry and write-off other inventory related assets.
Leases	Leases – The Company records rent expense for leases that contain scheduled rent increases on a straight-line basis over the lease term. When determining lease terms, the Company begins with the point at which the Company obtains control and possession of the leased property.
State Research and Development Credit Exchange Receivable	State Research and Development Credit Exchange Receivable — The State of Connecticut provides certain companies with the opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for foregoing the carryforward of the research and development credits (the “State Program”). The State Program provides for an exchange of research and development income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. Estimated amounts receivable under the State Program are recorded as a reduction of research and development expenses. These amounts are included in prepaid expenses and other current assets on the consolidated balance sheets. During the year ended December 31, 2017, there was no research and development tax credit. During the years ended December 31, 2016 and 2015, research and development expenses were offset by research and development tax credits of $0.2 million and $0.7 million, respectively.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets — As of December 31, 2017 and 2016, prepaid expenses and other current assets primarily consist of prepaid expenses for goods and services to be received and includes a certificate of deposit for $ 0.4 million as collateral as required by an agreement with the bank.
Assets Held for Sale	Assets Held for Sale — The Company classifies long-lived assets anticipated to be sold within one year as held for sale at the lower of their carrying value or fair value less estimated selling costs.
Property and Equipment	Property and Equipment — Property and equipment are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the term of the lease or the service lives of the improvements, whichever is shorter. Maintenance and repairs are expensed as incurred. Assets under construction are not depreciated until placed into service. Impairment of Long-Lived Assets — The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value may not be recoverable. If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss. The Company recorded an asset impairment of $0.2 million, $1.3 million and $140.6 million for the years ended December 31, 2017, 2016 and 2015, respectively (see Note 4 — Property and Equipment).
Recognized Loss on Purchase Commitments	Recognized Loss on Purchase Commitments — The Company assesses whether losses on long term purchase commitments should be accrued. Losses that are expected to arise from firm, non-cancellable, commitments for the future purchases are recognized unless recoverable. When making the assessment, the Company also considers whether it is able to renegotiate with its vendors. The recognized loss on purchase commitments is reduced as inventory items are received. If, subsequent to an accrual, a purchase commitment is successfully renegotiated, the gain is recognized in the Company’s consolidated statement of operations. During the year ended December 31, 2015, the Company recorded a loss on purchase commitments amounting to $116.2 million offset by $50 million expected to be recovered from Sanofi, primarily due to a long term purchase commitment for insulin raw materials. During the year ended December 31, 2016, the balance was adjusted for the recovery received from Sanofi, current purchases on the contracts and a reduction in the recognized loss related to amendments to purchase contracts. The balance of the recognized loss on insulin purchase commitments is $109.3 million as of December 31, 2017. No new contracts were identified in 2017 or 2016 requiring a new loss on purchase commitment accrual.
Milestone Rights Liability	Milestone Rights Liability — On July 1, 2013, in conjunction with the execution of the Facility Agreement, the Company issued Milestone Rights to Deerfield whereby the Company agreed to provide Deerfield with pre-specified Milestone Payments upon the achievement of 13 specific Milestone Events related to the commercial release and future cumulative net sales of Afrezza. The Company analyzed the Milestone Rights and determined that the agreement does not meet the definition of a freestanding derivative. Since the Company has not elected to apply the fair value option to the Milestone Rights Purchase Agreement, the Company recorded the Milestone Rights at their estimated initial fair value and accounted for the Milestone Rights as a liability. The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability will be remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, will be remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement will be recorded in the Company’s consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability will be reduced upon the settlement of each milestone payment. As a result, each milestone payment would be effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event (see Note 7 — Borrowings). As of December 31, 2017 and 2016, the remaining liability balance was $8.9 million.
Fair Value of Financial Instruments	Fair Value of Financial Instruments —The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 — Significant inputs to the valuation model are unobservable.
Income Taxes	Income Taxes — The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. Income tax positions are considered for uncertainty. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. If a tax position does not meet the minimum statutory threshold to avoid payment of penalties, the Company recognizes an expense for the amount of the penalty in the period the tax position is claimed in the tax return of the Company. The Company recognizes interest accrued related to unrecognized tax benefits in income tax expense, if any. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets, deferred tax liabilities, and any valuation allowance recorded against deferred tax assets. Due to uncertainties related to the realization of the Company’s deferred tax assets as a result of its history of operating losses, a full valuation allowance has been established against the total deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed. See Note 16 – Income Taxes for disclosure on the tax laws enacted in December 2017.
Contingencies	Contingencies — The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates.
Stock-Based Compensation	Stock-Based Compensation — Share-based payments to employees, including grants of stock options, restricted stock units, performance-based awards and the compensatory elements of employee stock purchase plans, are recognized in the consolidated statements of operations based upon the fair value of the awards at the grant date subject to an estimated forfeiture rate. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Restricted stock units are valued based on the market price on the grant date. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period.
Warrants	Warrants — The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument and evaluation of sufficient authorized shares available to satisfy the obligations. Warrants classified as derivative liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized in the consolidated statements of operations. The Company estimates the fair value of its derivative liabilities using a third party valuation analysis that utilizes a Monte Carlo pricing valuation model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as expected volatility, expected life, yield and a risk-free interest rate. Warrants classified as equity are recorded within additional paid in capital at the issuance date and are not re-measured in subsequent periods, unless the underlying assumptions change to trigger liability accounting. As of December 31, 2017, the outstanding warrants were de minimis. At December 31, 2016, the outstanding warrants were $ 7.4 million.
Comprehensive Income (Loss)	Comprehensive Income (Loss) — Other comprehensive income (loss) requires that all components of comprehensive income (loss) to be reported in the financial statements in the period in which they are recognized. Other comprehensive income (loss) includes certain changes in stockholders’ equity that are excluded from net income (loss). Specifically, the Company includes unrealized gains and losses on foreign exchange translation gains and losses resulting from translating cash and cash accounts in foreign currencies in accumulated other comprehensive loss on the consolidated balance sheets.
Research and Development Expenses	Research and Development Expenses — Research and development expenses consist of costs associated with the clinical trials of the Company’s product candidates, development supplies and other development materials, compensation and other expenses for research and development personnel, costs for consultants and related contract research, facility costs, and depreciation. Research and development costs, which are net of any tax credit exchange recognized for the Connecticut state research and development credit exchange program, are expensed as incurred.
Clinical Trial Expenses	Clinical Trial Expenses — Clinical trial expenses, which are reflected in research and development expenses in the accompanying consolidated statements of operations, result from obligations under contracts with vendors, consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The appropriate level of trial expenses are reflected in the Company’s consolidated financial statements by matching period expenses with period services and efforts expended. These expenses are recorded according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. Clinical trial accrual estimates are determined through discussions with internal clinical personnel and outside service providers as to the progress or state of completion of trials, or the services completed. Service provider status is then compared to the contractually obligated fee to be paid for such services. During the course of a clinical trial, the Company may adjust the rate of clinical expense recognized if actual results differ from management’s estimates.
Bonuses	Bonuses – The Company accounts for bonuses that require future service requirements by recognizing the compensation costs pro-rata over the period for which the service is rendered.
Interest Expense	Interest Expense — Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest cost capitalized for the year ended December 31, 2015 was $ 0.1 million. There were no capitalized interest costs for the years ended December 31, 2017 and 2016.
Net Income or (Loss) Per Share of Common Stock	Net Income (Loss) Per Share of Common Stock — Basic net income or loss per share excludes dilution for potentially dilutive securities and is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted net income or loss per share reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted net loss per share as they would be anti-dilutive.
Recently Issued Accounting Standards	Recently Issued Accounting Standards — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date The Company will adopt the new guidance for the year beginning January 1, 2018. The Company has the option to either apply the new guidance retrospectively for all prior reporting periods presented (full retrospective) or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective). The Company will apply the new guidance using the modified retrospective approach with the cumulative effect of initial application recognized as of January 1, 2018. Based on the expected impacts described below, the Company expects such cumulative effect adjustments to be $1.7 million decrease to the opening balance of accumulated deficit. The current accounting guidance requires the Company to reliably estimate returns in order to recognize revenue upon shipment. While we can currently estimate returns within a range, it is not sufficiently precise to meet the current requirements. Accordingly, the Company defers recognition of revenue on Afrezza product deliveries to wholesalers until the right of return no longer exists, which occurs at the earliest of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. For deliveries to wholesalers, the Company recognizes revenue based on estimated Afrezza patient prescriptions dispensed, a sell-through model. Upon adoption of the new guidance, the Company will move from its current sell-through model to a sell-to model for revenue related to commercial sales of Afrezza to wholesalers and will record revenue at the time title and risk of loss passes to its distributors (generally at delivery to the distributors) along with an estimate of potential returns as variable consideration. The Company also anticipates that its ability to estimate potential returns will improve with an additional three months of sales history that it will have obtained by the end of the first quarter of 2018. For sales of Afrezza to specialty pharmacies, the Company currently recognizes revenue at the time of shipment because specialty pharmacies generally purchase on demand and our estimated returns are minimal. The Company does not expect a material impact upon adoption for sales to specialty pharmacies. Additionally, the Company has historically entered into collaborative agreements with third parties under which periodic payments have been received. Revenue recognition for certain payments received have been deferred until the price is fixed and determinable. Further, revenue for certain payments to be received in the future has been prohibited from recognition until all contingencies have been resolved. The Company expects that some of these amounts will be considered variable consideration and may be able to be recognized earlier under the new guidance. The Company does not expect a material impact upon adoption for collaborative agreements. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 84 In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting. ASC 718 ASU 2017-09 In July 2017, the FASB issued ASU No. 2017-11, Earnings per Share (Topic 260) and Derivatives and Hedging (Topic 815): Accounting for Certain Financial Instruments with Down Round Provisions.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Components of Inventory	Inventories consist of the following (in thousands): December 31, 2017 2016 Raw materials $ 572 $ — Work-in-process 1,273 2,120 Finished goods 812 211 Total inventory $ 2,657 $ 2,331

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment, Net	Property and equipment consist of the following (in thousands): Estimated Useful December 31, Life (Years) 2017 2016 Land — $ 875 $ 875 Buildings 39-40 17,389 17,389 Building improvements 5-40 34,957 34,957 Machinery and equipment 3-15 62,681 62,992 Furniture, fixtures and office equipment 5-10 3,556 3,556 Computer equipment and software 3 8,416 8,531 Construction in progress — — 202 127,874 128,502 Less accumulated depreciation (100,952 ) (99,575 ) Total property and equipment, net $ 26,922 $ 28,927

Accrued Expenses and Other Cu31

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following (in thousands): December 31, 2017 2016 Salary and related expenses $ 7,260 $ 3,814 Current portion of milestone rights liability 1,643 — Professional fees 1,007 875 Discounts and allowances for commercial product sales 873 754 Sales and marketing services 147 144 Restructuring 362 1,376 Accrued interest 567 619 Other 590 355 Accrued expenses and other current liabilities $ 12,449 $ 7,937

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Summary of Borrowings	Borrowings consist of the following (in thousands): December 31, 2017 2016 Facility Financing Obligation (2019 Notes and Tranche B Notes) Principal amount $ 54,407 $ 75,000 Unamortized debt issuance costs and debt discount (1,662 ) (3,661 ) Net carrying amount $ 52,745 $ 71,339 Senior Convertible Notes (2021 Notes) Principal amount $ 23,690 $ 27,690 Unamortized premium 721 426 Unaccreted debt issuance costs — (481 ) Net carrying amount $ 24,411 $ 27,635 Note payable to principal stockholder - net carrying amount $ 79,666 $ 49,521
Accretion of Debt Issuance Cost and Debt Discount	Accretion of debt issuance cost and debt discount in connection with the Facility Agreement does not include the acceleration of the debt discount and issuance costs related to the transactions disclosed above as the amounts were included in the loss on extinguishment of debt in the consolidated statement of operations. Accretion of debt issuance cost and debt discount during the years ended December 31, 2017, 2016 and 2015 were as follows (in thousands): December 31, 2017 2016 2015 Accretion expense - debt issuance cost $ 31 $ 35 35 Accretion expense - debt discount $ 1,700 $ 1,722 1,553

Fair Value of Financial Instr33

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	The following tables set forth the fair value of the Company’s financial instruments (in millions): As of December 31, 2017 Fair Value Measurements Using Carrying Amount Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Financial liabilities: Senior convertible notes (2021 notes) $ 24.4 $ — $ — $ 19.8 $ 19.8 Facility financing obligation 52.7 — — 54.6 54.6 Milestone rights 8.9 — — 19.1 19.1 Total financial liabilities $ 86.0 $ — $ — $ 93.5 $ 93.5 As of December 31, 2016 Fair Value Measurements Using Carrying Value Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Financial liabilities: Senior convertible notes (2018 notes) $ 27.6 $ — $ — $ 22.9 $ 22.9 Facility financing obligation 71.3 — — 74.5 74.5 Milestone rights 8.9 — — 18.4 18.4 Warrant liability (at recurring fair value) 7.4 — — 7.4 7.4 Total financial liabilities $ 115.2 $ — $ — $ 123.2 $ 123.2
Fair Values of Financial Liabilities which Include Level 3 Instruments	The following table provides a roll forward of the fair values of financial assets and liabilities that are carried at fair value (in millions): Warrants Assets Held for Sale Fair value, January 1, 2016 $ — $ — Additions 12.8 17.3 Changes in fair value (5.4 ) (0.6 ) Payments — — Fair value, December 31, 2016 $ 7.4 $ 16.7 Additions — — Changes in fair value (5.5 ) — Settlement through exchange of common shares (1.9 ) Payments — (16.7 ) Fair value, December 31, 2017 $ — $ —

Net Income (Loss) Per Common 34

Net Income (Loss) Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Components of Basic and Diluted Net Income (Loss) Per Common Share Computations	The following tables summarize the components of the basic and diluted net income (loss) per common share computations (in thousands, except per share amounts): Year Ended December 31, 2017 2016 2015 Basic EPS: Net (loss) income (numerator) $ (117,333 ) $ 125,664 $ (368,445 ) Weighted average common shares (denominator) 104,245 92,053 81,233 Net (loss) income per share $ (1.13 ) $ 1.37 $ (4.54 ) Diluted EPS: Net (loss) income (numerator) $ (117,333 ) $ 125,664 $ (368,445 ) Weighted average common shares 104,245 92,053 81,233 Effect of dilutive securities - common shares issuable — 32 — Adjusted weighted average common shares (denominator) 104,245 92,085 81,233 Net (loss) income per share $ (1.13 ) $ 1.36 $ (4.54 )
Potential Dilutive Securities Outstanding that are Considered Antidilutive	Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares): December 31, 2017 2016 2015 Exercise of common stock options 7,089,440 5,530,256 3,955,845 Conversion of convertible notes into common stock 6,875,272 814,561 814,561 Employee stock purchase plan 136,660 43,672 33,986 Exercise of common stock warrants 31,856 9,740,597 814,919 Vesting of restricted stock units 1,135,216 702,867 360,924 15,268,444 16,831,953 5,980,235

Stock Award Plans (Tables)

Stock Award Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Award Plans	The following table summarizes information about the Company’s stock-based award plans as of December 31, 2017: Outstanding Options Outstanding Restricted Stock Units Shares Available for Future Issuance 2004 Equity Incentive Plan 1,231,740 — — 2013 Equity Incentive Plan 5,795,035 1,135,216 1,509,343 2004 Non-Employee Directors’ Stock Option Plan 62,665 — — Total 7,089,440 1,135,216 1,509,343
Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations	Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is as follows (in thousands): Year Ended December 31, 2017 2016 2015 Employee-related $ 4,847 $ 5,135 $ 8,407 Consultant-related — — 318 Total $ 4,847 $ 5,135 $ 8,725
Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category	Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is included in the following categories (in thousands): Year Ended December 31, 2017 2016 2015 Cost of goods sold $ 460 $ 695 $ — Research and development 1,010 1,309 3,029 Selling, general and administrative 3,377 3,131 5,696 Total $ 4,847 $ 5,135 $ 8,725
Assumptions Used to Calculate Fair Value of Employee Stock Options	The Company calculated the fair value of employee stock options granted during the years ended December 31, 2017, 2016 and 2015 using the following assumptions: Year Ended December 31, 2017 2016 2015 Risk-free interest rate 1.83% — 2.13% 1.18% — 1.80% 1.61% —1.86% Expected lives 5.41 — 5.78 years 5.13 — 5.82 years 5.79 — 5.86 years Volatility 83.32% — 90.39% 77.57% — 82.75% 69.76% — 71.84% Dividends — — —
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding: Number of Shares Weighted Average Exercise Price per Share Aggregate Intrinsic Value ($000) Outstanding at January 1, 2017 5,530,256 $ 16.10 Granted 3,335,385 1.60 Exercised (5,300 ) 4.55 Forfeited (598,204 ) 3.17 Expired (1,172,697 ) 22.21 Outstanding at December 31, 2017 7,089,440 $ 9.33 $ 2,484 Vested and expected to vest at December 31, 2017 6,735,675 $ 9.70 $ 2,262 Exercisable at December 31, 2017 2,813,227 $ 19.52 $ 61
Summary of Restricted Stock Unit Activity	A summary of restricted stock unit activity for the year ended December 31, 2017 is presented below: Number of Shares Weighted Average Grant Date Fair Value per Share Outstanding at January 1, 2017 737,966 $ 8.40 Granted 669,091 1.36 Vested (192,361 ) 10.02 Forfeited (79,480 ) 5.89 Outstanding at December 31, 2017 1,135,216 $ 4.08

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Annual Purchase Requirements under Contract	The annual purchase requirements under the contract are as follows: 2018 € 8.9 million 2019 € 11.6 million 2020 € 15.5 million 2021 € 15.5 million 2022 € 19.4 million 2023 € 19.4 million
Schedule of Future Minimum Lease Payments	Future minimum lease payments are as follows: 2018 $ 522,000 2019 947,000 2020 976,000 2021 1,005,000 2022 1,035,000 Thereafter 88,000 $ 4,573,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Loss from Continuing Operations Before Provision for Income Tax	Loss from continuing operations before provision for income tax for the Company’s domestic and international operations was as follows (in thousands): December 31, 2017 2016 2015 US $ (113,679 ) $ 129,361 $ (358,047 ) Foreign (3,603 ) (3,697 ) (10,398 ) Loss before provision for income taxes $ (117,282 ) $ 125,664 $ (368,445 )
Provision for Income Taxes	The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2017 2016 2015 Current U.S. federal $ 51 $ — $ — U.S. state — — — Non-U.S. — — — Total current 51 — — Deferred U.S. federal 244,801 (43,814 ) 109,512 U.S. state 15,398 (4,311 ) (29,394 ) Non-U.S. — — — Total deferred 260,199 (48,125 ) 80,118 Valuation allowance (260,199 ) 48,125 (80,118 ) Total $ 51 $ — $ —
Components of Net Deferred Tax Assets	Components of the net deferred tax assets as of December 31, 2017 and 2016, are as follows (in thousands): December 31, 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 507,235 $ 712,124 Research and development credits 83,461 77,998 Capitalized research 1,016 5,117 Milestone Rights 1,908 3,242 Accrued expenses 211 440 Loss on purchase commitment 23,654 36,775 Non-qualified stock option expense 7,004 17,331 Capitalized patent costs 5,194 8,781 Other 795 7,380 Depreciation 23,820 45,310 Total net deferred tax assets 654,298 914,498 Valuation allowance (654,298 ) (914,498 ) Net deferred tax assets $ — $ —
Effective Income Tax Rate	The Company’s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December 31, 2017, 2016 and 2015: December 31, 2017 2016 2015 Federal tax benefit rate 35.0 % 35.0 % 35.0 % Permanent items 6.2 (1.9 ) — Intercompany transfer of intellectual property — 0.9 (1.0 ) 2017 tax law changes (265.0 ) — — Stock based compensation (5.0 ) — — Tax attribute expirations (2.8 ) — — Valuation allowance 231.6 (34.0 ) (34.0 ) Effective income tax rate — % — % — %

Restructuring Charges (Tables)

Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges	A reconciliation of beginning and ending liability balances for the restructuring charges is as follows (in thousands): Description 2016 Restructuring 2015 Restructuring Total Accrual — January 1, 2016 $ — $ 3,028 $ 3,028 Costs incurred and charged to expense 1,475 560 2,035 Costs paid or settled (1,266 ) (2,421 ) (3,687 ) Accrual — December 31, 2016 209 1,167 1,376 Costs incurred and charged to expense — — — Costs paid or settled (209 ) (805 ) (1,014 ) Accrual — December 31, 2017 $ — $ 362 $ 362

Selected quarterly financial 39

Selected quarterly financial data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data	Summarized quarterly financial data for the years ended December 31, 2017 and 2016, are set forth in the following tables: March 31 June 30 September 30 December 31 (In thousands, except per share data) 2017 Net revenues $ 3,009 $ 2,163 $ 2,043 $ 4,530 Net (loss) $ (16,324 ) $ (35,339 ) $ (32,886 ) (32,784 ) Net (loss) per share — basic $ (0.17 ) $ (0.35 ) $ (0.31 ) $ (0.28 ) Net (loss) per share — diluted $ (0.17 ) $ (0.35 ) $ (0.31 ) $ (0.28 ) Weighted average common shares used to compute basic net (loss) per share 95,744 99,864 104,703 116,451 Weighted average common shares used to compute diluted net (loss) per share 95,744 99,864 104,703 116,451 2016 Net revenues $ — $ — $ 162,354 $ 12,404 Net income (loss) $ (24,873 ) $ (29,959 ) $ 126,520 $ 53,976 Net income (loss) per share — basic $ (0.29 ) $ (0.33 ) $ 1.32 $ 0.56 Net income (loss) per share — diluted (0.29 ) $ (0.33 ) 1.31 0.56 Weighted average common shares used to compute basic net income (loss) per share 85,771 91,061 95,627 95,676 Weighted average common shares used to compute diluted net income (loss) per share 85,771 91,061 96,548 96,510

Description of Business - Addit

Description of Business - Additional Information (Detail)	Mar. 01, 2017shares	Dec. 31, 2017USD ($)shares	Dec. 13, 2017shares	Jun. 29, 2017USD ($)	Dec. 31, 2016USD ($)shares	Sep. 30, 2016shares	Dec. 31, 2015USD ($)	Jan. 01, 2015USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit		$ (2,854,898,000)			$ (2,737,565,000)
Cash and cash equivalents		43,946,000			$ 22,895,000
Principal amount of outstanding borrowings		$ 157,800,000
Stock split of common stock	0.2
Reverse stock split, description		The Company’s board of directors approved a 1-for-5 reverse stock split of its outstanding common stock. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
Common stock, shares authorized | shares	140,000,000	280,000,000	280,000,000		140,000,000	700,000,000
Common stock		$ 1,192,000			$ 957,000
Additional paid-in capital		2,638,992,000			2,553,039,000
Adjustments
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock					(3,800,000)		$ (3,400,000)	$ (3,200,000)
Additional paid-in capital					3,800,000		$ 3,400,000	$ 3,200,000
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, shares authorized | shares			280,000,000
Minimum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, shares authorized | shares			140,000,000
Senior convertible notes due December 31, 2019 | Less portion of commitment asset
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount of outstanding borrowings		$ 54,407,000			$ 75,000,000
Deerfield | Less portion of commitment asset
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate					8.75%
Deerfield | Senior convertible notes due December 31, 2019
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate		9.75%
Principal amount of outstanding borrowings		$ 39,400,000			$ 55,000,000
Deerfield | Senior convertible notes due December 31, 2019 | Less portion of commitment asset
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate		8.75%
Principal amount of outstanding borrowings		$ 15,000,000			$ 20,000,000
Deerfield | Senior convertible notes due December 31, 2019 | Minimum | Less portion of commitment asset
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Available amount of credit facility under covenant restrictions		$ 25,000,000
Deerfield | Senior convertible notes due December 31, 2019 | Minimum | Less portion of commitment asset | Third Amendment [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Available amount of credit facility under covenant restrictions				$ 10,000,000

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, € in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017USD ($)Distributor	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)Distributor	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2017USD ($)Distributor$ / shares	Dec. 31, 2017EUR (€)Distributor	Dec. 31, 2016USD ($)Distributor	Dec. 31, 2015USD ($)	Jan. 01, 2018USD ($)
Summary Of Significant Accounting Policies [Line Items]
Net (loss) income	$ (32,784,000)	$ (32,886,000)	$ (35,339,000)	$ (16,324,000)	$ 53,976,000	$ 126,520,000	$ (29,959,000)	$ (24,873,000)	$ (117,333,000)		$ 125,664,000	$ (368,445,000)
Net revenue - commercial product sales	1,200,000								9,192,000		1,895,000
Net deferred revenue	$ 3,038,000				3,419,000				$ 3,038,000		3,419,000
Number of wholesale distributors | Distributor									3	3
Percentage of product shipments to wholesale distributors									89.00%	89.00%
Deferred revenue from sale of raw insulin									$ 0		1,700,000
Cash discount as incentive for prompt payment	2.00%								2.00%
Revenue - other									$ 2,303,000		$ 898,000
Maturity period of cash equivalents									90 days or less at the time of purchase	90 days or less at the time of purchase	90 days from the date of purchase
Allowance for doubtful accounts	$ 0				$ 0				$ 0		$ 0
Number of wholesale distributors accounted for gross accounts receivable | Distributor	3				3				3		3
Percentage of accounts receivable from major wholesale distributors	93.00%				95.00%				93.00%		95.00%
Inventory charge									$ 3,000,000		$ 0	39,300,000
Percentage of credit exchange receivable									65.00%	65.00%
Estimated amounts receivable under program	$ 0				$ 200,000				$ 0		200,000	700,000
Prepaid expenses and other current assets	3,010,000				4,364,000				$ 3,010,000		4,364,000
Long-lived assets anticipated sale in year									1 year	1 year
Asset impairment charge									$ 200,000		1,300,000	140,600,000
Purchase commitment obligation	109,300,000								$ 109,300,000			116,200,000
Long term purchase commitment | €										€ 90.3
Revenue recognition, milestone method, number of milestone									13	13
Liability for uncertainty in income taxes	0								$ 0
Outstanding warrants					7,400,000						7,400,000
Interest cost capitalized									$ 0		0	100,000
Lessee, term of contract									12 months	12 months
Restricted cash balances	4,400,000				0				$ 4,400,000		0
Accumulated Deficit
Summary Of Significant Accounting Policies [Line Items]
Net (loss) income									(117,333,000)		125,664,000	(368,445,000)
Accumulated Deficit | Subsequent Event
Summary Of Significant Accounting Policies [Line Items]
Cumulative effect adjustments on accumulated deficit													$ 1,700,000
Sanofi-Aventis Deutschland GmbH
Summary Of Significant Accounting Policies [Line Items]
Long term purchase commitment												$ 50,000,000
Deerfield | Milestone Rights Liability | Senior convertible notes due December 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Long term liability	8,900,000				8,900,000				8,900,000		8,900,000
Certificates of Deposit
Summary Of Significant Accounting Policies [Line Items]
Prepaid expenses and other current assets	400,000				400,000				400,000		400,000
Intellectual property
Summary Of Significant Accounting Policies [Line Items]
Revenue - other			$ 600,000						600,000
Third party logistics
Summary Of Significant Accounting Policies [Line Items]
Net deferred revenue	$ 1,500,000				$ 800,000				1,500,000		800,000
Inventory in Distribution Channel
Summary Of Significant Accounting Policies [Line Items]
Net (loss) income									$ 1,200,000
Basic and diluted net income (loss) per share | $ / shares									$ 0.01
AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Product sales revenue gross to net adjustments									$ 3,400,000		$ 800,000
Product sales revenue gross to net adjustments percentage									27.00%	27.00%	30.00%
AFREZZA product sales | Sales through Specialty Pharmacies
Summary Of Significant Accounting Policies [Line Items]
Net revenue - commercial product sales									$ 500,000
Bulk insulin sales
Summary Of Significant Accounting Policies [Line Items]
Revenue - other									$ 1,700,000
Minimum | AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months									6 months	6 months
Maximum | AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months									12 months	12 months

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 572
Work-in-process	1,273	$ 2,120
Finished goods	812	211
Total inventory	$ 2,657	$ 2,331

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory write-down	$ 2,971,000	$ 0	$ 36,104,000

Property and Equipment, Net (De

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 127,874	$ 128,502
Less accumulated depreciation	(100,952)	(99,575)
Total property and equipment, net	26,922	28,927
Land
Property Plant And Equipment [Line Items]
Property and equipment - gross	875	875
Buildings
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 17,389	17,389
Buildings | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	39 years
Buildings | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Building Improvements
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 34,957	34,957
Building Improvements | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Building Improvements | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 62,681	62,992
Machinery and Equipment | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Machinery and Equipment | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	15 years
Furniture, fixtures and office equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 3,556	3,556
Furniture, fixtures and office equipment | Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Furniture, fixtures and office equipment | Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	10 years
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Property and equipment - gross	$ 8,416	8,531
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment - gross		$ 202

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	Feb. 17, 2017	Jan. 06, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Depreciation and Other Amortization Expenses [Line Items]
Depreciation and amortization expense			$ 1,800	$ 2,400	$ 11,000
Impairment charge			200	1,300	140,600
Property and equipment impairment			203	1,259	140,412
Cash received from property, plant and equipment			$ 24	17	82
Property and Equipment Impairment
Depreciation and Other Amortization Expenses [Line Items]
Property and equipment impairment				700
Asset held for sale
Depreciation and Other Amortization Expenses [Line Items]
Impairment charge				600
Danbury Facility
Depreciation and Other Amortization Expenses [Line Items]
Impairment charge					$ 138,600
Land, Buildings and Improvements | California
Depreciation and Other Amortization Expenses [Line Items]
Amount of divestiture of long-lived		$ 17,300
Cash received from property, plant and equipment	$ 17,300
Net cash received from property, plant and equipment		16,700
Payments for commissions and other fees		$ 600
Carrying value of the asset held for sale				$ 16,700

Accrued Expenses and Other Cu46

Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accrued Expenses And Other Current Liabilities [Abstract]
Salary and related expenses	$ 7,260	$ 3,814
Current portion of milestone rights liability	1,643
Professional fees	1,007	875
Discounts and allowances for commercial product sales	873	754
Sales and marketing services	147	144
Restructuring	362	1,376	$ 3,028
Accrued interest	567	619
Other	590	355
Accrued expenses and other current liabilities	$ 12,449	$ 7,937

Related-Party Arrangements - Ad

Related-Party Arrangements - Additional Information (Detail)	Oct. 23, 2017shares	Oct. 10, 2017shares	May 31, 2015USD ($)ft²	Oct. 31, 2013USD ($)	Oct. 31, 2007USD ($)	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)shares	Jun. 30, 2017USD ($)
Related Party Transaction [Line Items]
Interest expense						$ 3,782,000	$ 2,901,000	$ 2,894,000
Common Stock
Related Party Transaction [Line Items]
Number of shares sold in underwritten public offering | shares	973,236					173,000		1,788,000
Loan Arrangement
Related Party Transaction [Line Items]
Amount available for future borrowings						$ 0	30,100,000
Purchase Agreements
Related Party Transaction [Line Items]
Stock purchase agreements date		Oct. 10, 2017
Purchase Agreements | Common Stock
Related Party Transaction [Line Items]
Number of shares sold in underwritten public offering | shares		10,166,600
Charitable Foundation | Common Stock | Director
Related Party Transaction [Line Items]
Number of shares sold in underwritten public offering | shares		166,600
Principal stockholder
Related Party Transaction [Line Items]
Loan agreement with related party				$ 370,000,000	$ 350,000,000
Principal stockholder | Amended Agreement
Related Party Transaction [Line Items]
Maturity date						Jan. 5, 2020
Principal stockholder | Loan Arrangement
Related Party Transaction [Line Items]
Accrued interest of related party debt						$ 2,300,000	9,300,000		$ 10,700,000
Available amount of credit facility under covenant restrictions									$ 19,400,000
Fixed borrowing rate						5.84%
Related party transaction prepayment period						90 days
Aggregate principal amount cancelled						$ 105,000,000
Principal amount outstanding under credit facility						79,700,000	49,500,000
Principal stockholder | Loan Arrangement | Maximum
Related Party Transaction [Line Items]
Amount prepaid for cancellation of indebtedness						$ 200,000,000
Principal stockholder | Loan Arrangement | Minimum
Related Party Transaction [Line Items]
Number of months advances outstanding						12 months
Related Party Debt | Letter Agreement
Related Party Transaction [Line Items]
Description of variable rate interest						the interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum.
Related Party Debt | Letter Agreement | LIBOR
Related Party Transaction [Line Items]
Interest rate (LIBOR)						5.00%
Mann Foundation | Sublease Agreement
Related Party Transaction [Line Items]
Lease expiration date						Aug. 31, 2017
Mann Foundation | Sublease Agreement
Related Party Transaction [Line Items]
Area of office space leased | ft²			12,500
Lease expiration period						2017-04
Amount of leases renewed per month			$ 20,000
Lease payments						$ 200,000	$ 300,000	$ 200,000

Summary of Borrowings (Detail)

Summary of Borrowings (Detail) - USD ($)	Dec. 31, 2017	Oct. 23, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Principal amount	$ 157,800,000
Note payable to principal stockholder - net carrying amount	79,666,000		$ 49,521,000
Senior convertible notes due December 31, 2019 | Tranche B Notes
Debt Instrument [Line Items]
Principal amount	54,407,000		75,000,000
Unamortized debt issuance costs and debt discount	(1,662,000)		(3,661,000)
Net carrying amount	52,745,000		71,339,000
5.75% Senior convertible notes due October 23, 2021
Debt Instrument [Line Items]
Principal amount	23,690,000	$ 23,690,000	27,690,000
Unamortized premium	721,000	$ 800,000	426,000
Unaccreted debt issuance costs			(481,000)
Net carrying amount	$ 24,411,000		$ 27,635,000

Borrowings - Additional Informa

Borrowings - Additional Information (Detail)	Nov. 06, 2017USD ($)$ / sharesshares	Oct. 23, 2017USD ($)d$ / sharesshares	Jun. 29, 2017USD ($)$ / sharesshares	Apr. 18, 2017USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Jul. 01, 2013USD ($)
Debt Instrument [Line Items]
Principal amount							$ 157,800,000
Cash repayment of senior notes under exchange agreement									$ 64,287,000
Loss on extinguishment of debt							1,611,000	$ (72,024,000)	1,049,000
Cash and cash equivalents							43,946,000	22,895,000
Facility Agreement, total principle payment in 2018							24,400,000
Facility Agreement, total principle payment in 2019							30,000,000
Interest expense on notes							9,494,000	15,576,000	21,231,000
Carrying value of the milestone rights liability							12,449,000	7,937,000
Other liabilities							$ 93,500,000	$ 123,200,000
Common stock, shares issued | shares							119,053,414	95,680,831
Accretion expense - debt discount							$ 1,700,000	$ 1,722,000	$ 1,553,000
Common Stock
Debt Instrument [Line Items]
Number of shares sold in underwritten public offering | shares		973,236					173,000		1,788,000
Milestone Rights Liability
Debt Instrument [Line Items]
Other liabilities							$ 19,100,000	$ 18,400,000
Deerfield
Debt Instrument [Line Items]
Principal repayment schedule, start date							Jul. 1, 2016
Principal repayment schedule, end date							Dec. 9, 2019
Deerfield | Less portion of commitment asset
Debt Instrument [Line Items]
Senior notes, effective interest rate								8.75%
Deerfield | Milestone Rights Liability
Debt Instrument [Line Items]
Long term liability							$ 8,900,000
Deerfield | Milestone Rights Liability | Maximum
Debt Instrument [Line Items]
Contingent liability for milestone payments							90,000,000			$ 90,000,000
Senior convertible notes due December 31, 2019
Debt Instrument [Line Items]
Exchange price per share | $ / shares			$ 1.45	$ 1.22
Loss on extinguishment of debt			$ 5,000,000
Cash repayment				$ 4,000,000
Debt extinguishment amount			500,000
Debt discount and issuance costs			300,000
Senior convertible notes due December 31, 2019 | Less portion of commitment asset
Debt Instrument [Line Items]
Principal amount							54,407,000	$ 75,000,000
Loss on extinguishment of debt				300,000
Senior convertible notes due December 31, 2019 | Deerfield
Debt Instrument [Line Items]
Principal amount							$ 39,400,000	55,000,000
Senior notes, effective interest rate							9.75%
Carrying value of the milestone rights liability							$ 1,600,000
Other liabilities							8,900,000	8,900,000
Senior convertible notes due December 31, 2019 | Deerfield | Facility Agreement Third Amendment [Member]
Debt Instrument [Line Items]
Cash repayment of senior notes under exchange agreement			10,000,000
Conversion of notes to common shares, value			$ 5,000,000
Conversion Option, shares | shares			3,584,230
Exchange price per share | $ / shares			$ 1.395
Cash and cash equivalents			$ 10,000,000
Senior convertible notes due December 31, 2019 | Deerfield | Minimum | Facility Agreement Third Amendment [Member]
Debt Instrument [Line Items]
Cash and cash equivalents			$ 25,000,000				10,000,000
Senior convertible notes due December 31, 2019 | Deerfield | Less portion of commitment asset
Debt Instrument [Line Items]
Principal amount							$ 15,000,000	20,000,000
Senior notes, effective interest rate							8.75%
Cash repayment of senior notes under exchange agreement				4,000,000
Conversion of notes to common shares, value				$ 1,000,000
Senior convertible notes due December 31, 2019 | Deerfield | Tranche B Exchange Shares
Debt Instrument [Line Items]
Conversion Option, shares | shares				869,565
Exchange price per share | $ / shares				$ 1.15
Senior convertible notes due December 31, 2019 | Deerfield | Tranche B Exchange Shares | Fourth Amendment to Facility Agreement
Debt Instrument [Line Items]
Conversion of notes to common shares, value	$ 5,592,750
Conversion Option, shares | shares	1,720,846
Conversion price of shares | $ / shares	$ 3.25
Senior convertible notes due December 31, 2019 | Deerfield | Tranche 1 Notes
Debt Instrument [Line Items]
Conversion of notes to common shares, value				$ 5,000,000
Conversion Option, shares | shares				4,347,826
Senior convertible notes due December 31, 2019 | Deerfield | Milestone Rights Liability
Debt Instrument [Line Items]
Short term liability										3,200,000
Long term liability							$ 7,200,000	8,900,000		$ 13,100,000
Interest expense on notes						$ 5,800,000
Required payment pursuant to the terms of the Milestone Agreement						$ 10,000,000
Senior convertible notes due December 31, 2019 | Deerfield | Milestone Rights Liability | Scenario Forecast
Debt Instrument [Line Items]
Required payment pursuant to the terms of the Milestone Agreement					$ 5,000,000
2019 Notes and Tranche B Notes
Debt Instrument [Line Items]
Other liabilities							54,600,000	74,500,000
2019 Notes and Tranche B Notes | Fourth Amendment to Facility Agreement
Debt Instrument [Line Items]
Deferred payment of credit facility principal amount		$ 10,000,000
2019 Notes and Tranche B Notes | Deerfield | Tranche B Exchange Shares | Fourth Amendment to Facility Agreement
Debt Instrument [Line Items]
Number of trading days | d		3
Conversion price of shares | $ / shares		$ 3.25
2019 Notes and Tranche B Notes | Deerfield | Tranche B Exchange Shares | Maximum | Common Stock | Fourth Amendment to Facility Agreement
Debt Instrument [Line Items]
Number of shares sold in underwritten public offering | shares		4,000,000
5.75% Senior convertible notes due August 15, 2018
Debt Instrument [Line Items]
Principal amount		$ 27,690,000
Senior notes, effective interest rate		5.75%
Loss on extinguishment of debt							800,000
Debt discount and issuance costs							200,000	300,000
Conversion price of shares | $ / shares		$ 34
Other liabilities								22,900,000
Unamortized debt issuance costs							300,000
Unamortized premium							200,000
Accretion expense - debt discount							200,000	200,000
5.75% Senior convertible notes due October 23, 2021
Debt Instrument [Line Items]
Principal amount		$ 23,690,000					23,690,000	27,690,000
Senior notes, effective interest rate		5.75%
Number of trading days | d		10
Conversion price of shares | $ / shares		$ 5.15
Other liabilities							19,800,000
Unamortized debt issuance costs								481,000
Unamortized premium		$ 800,000					721,000	$ 426,000
No of convertible shares		194.1748
Principal amount per share | $ / shares		$ 1,000
Percentage of repurchase price		100.00%
Percentage of conversion price equaling stock price		120.00%
Consecutive trading days | d		20
Debt instrument, convertible, threshold business days		5 years
Accretion expense - debt discount							$ 30,000
5.75% Senior convertible notes due October 23, 2021 | Maximum
Debt Instrument [Line Items]
Common stock, shares issued | shares		13,648,300

Accretion of Debt Issuance Cost

Accretion of Debt Issuance Cost and Debt Discount (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Accretion expense - debt issuance cost	$ 31	$ 35	$ 35
Accretion expense - debt discount	$ 1,700	$ 1,722	$ 1,553

Collaboration Arrangements - Ad

Collaboration Arrangements - Additional Information (Detail)

Dec. 30, 2016USD ($)

Nov. 09, 2016USD ($)

Sep. 30, 2016USD ($)

Apr. 04, 2016

Feb. 10, 2016USD ($)

Jan. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2016USD ($)

Sep. 30, 2016USD ($)

Dec. 31, 2017USD ($)Milestone

Dec. 31, 2016USD ($)Milestone

Dec. 31, 2015USD ($)

Sep. 23, 2014USD ($)

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Net revenue from collaboration

$ 250,000

$ 171,965,000

Secured loan facility, amount borrowed

19,429,000

Interest incurred through borrowings under Sanofi Loan Facility

4,478,000

$ 1,652,000

Gain on extinguishment of debt

(1,611,000)

72,024,000

(1,049,000)

Insulin Put

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Net revenue from collaboration

$ 10,200,000

Sanofi-Aventis Deutschland GmbH | Put Option

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Payment for insulin put option

$ 30,600,000

30,600,000

Aventisub LLC

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Outstanding loan balance forgiven

$ 72,000,000

Receptor

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Nonrefundable payments

400,000

Nonrefundable option exercise and license fee

$ 1,000,000

Reduction in research and development expense

400,000

Net revenue from collaboration

300,000

Deferred revenue - nonrefundable license fee

$ 1,000,000

Deferred revenue recognition period

4 years

License and Collaboration Agreement with Sanofi

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Profits and losses sharing percentage

35.00%

Termination date

Apr. 4, 2016

Maximum secured loan facility

$ 175,000,000

Senior notes, effective interest rate

8.50%

Gain on extinguishment of debt

$ 500,000

License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Net revenue from collaboration

$ 10,200,000

$ 161,800,000

$ 172,000,000

Deferred revenue - nonrefundable license fee

$ 150,000,000

Profits and losses sharing percentage

65.00%

Number of milestone | Milestone

2

2

Milestone receivable

$ 25,000,000

Deferred cost

13,500,000

Secured loan facility, amount borrowed

$ 17,900,000

44,500,000

Secured loan facility, amount owed

$ 71,200,000

$ 71,200,000

Interest incurred through borrowings under Sanofi Loan Facility

$ 5,800,000

Gain on extinguishment of debt

$ 72,000,000

License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Net revenue from collaboration

$ (64,900,000)

Company's total portion of loss sharing

57,700,000

License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Net revenue from collaboration

17,500,000

Deferred revenue - nonrefundable license fee

$ 17,500,000

License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Up Front Payment [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Net revenue from collaboration

150,000,000

License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment One

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Net revenue from collaboration

25,000,000

License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment Two

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Net revenue from collaboration

25,000,000

License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Insulin Put

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Net revenue from collaboration

$ 19,400,000

Sale of Intellectual Property -

Sale of Intellectual Property - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Finite Lived Intangible Assets [Line Items]
Revenue - other			$ 2,303,000	$ 898,000
Intellectual property
Finite Lived Intangible Assets [Line Items]
Proceeds from royalties	$ 600,000
Revenue - other		$ 600,000	600,000
Royalty revenue			$ 0

Fair Value of Financial Instr53

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Jul. 01, 2013
Fair Value Of Financial Instruments [Line Items]
Cash equivalents, money market funds	$ 41,000,000	$ 20,500,000
Fair value of the liability, percentage decrease	4.00%
Milestone Rights Liability | Deerfield
Fair Value Of Financial Instruments [Line Items]
Long term liability	$ 8,900,000
Minimum
Fair Value Of Financial Instruments [Line Items]
Probabilities of meeting the milestones, amount	$ 50,000,000
Probabilities of meeting the milestones, percentage decrease	5.00%
Fair value of the liability, percentage decrease	14.00%
Maximum
Fair Value Of Financial Instruments [Line Items]
Probabilities of meeting the milestones, amount	$ 200,000,000
Probabilities of meeting the milestones, percentage decrease	10.00%
Fair value of the liability, percentage decrease	28.00%
Senior convertible notes due December 31, 2019 | Milestone Rights Liability | Deerfield
Fair Value Of Financial Instruments [Line Items]
Long term liability	$ 7,200,000	$ 8,900,000	$ 13,100,000
Fair Value, Inputs, Level 3 | Milestone Rights Liability
Fair Value Of Financial Instruments [Line Items]
Fair value of warrants liability	$ 19,100,000
Fair Value, Inputs, Level 3 | Market Approach Valuation Technique | 5.75% Senior convertible notes due October 23, 2021 | Senior Convertible Notes
Fair Value Of Financial Instruments [Line Items]
Fair value assumption, risk-free rate	20.00%
Fair value assumption, stock price volatility	102.00%
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Milestone Rights Liability
Fair Value Of Financial Instruments [Line Items]
Market discount rate	14.00%
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Senior convertible notes due December 31, 2019 | Minimum
Fair Value Of Financial Instruments [Line Items]
Market discount rate	12.00%
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Senior convertible notes due December 31, 2019 | Maximum
Fair Value Of Financial Instruments [Line Items]
Market discount rate	13.00%

Fair Value of Financial Instr54

Fair Value of Financial Instruments (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Financial liabilities:
Financial liabilities fair value	$ 93.5	$ 123.2
Warrant Liability
Financial liabilities:
Financial liabilities fair value	0	7.4	$ 0
Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	19.1	18.4
Carrying Value
Financial liabilities:
Financial liabilities fair value	86	115.2
Carrying Value | Warrant Liability
Financial liabilities:
Financial liabilities fair value		7.4
Carrying Value | Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	8.9	8.9
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	93.5	123.2
Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3 | Warrant Liability
Financial liabilities:
Financial liabilities fair value		7.4
Estimate of Fair Value Measurement | Milestone Rights Liability | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	19.1	18.4
5.75% Senior convertible notes due October 23, 2021
Financial liabilities:
Financial liabilities fair value	19.8
5.75% Senior convertible notes due October 23, 2021 | Carrying Value
Financial liabilities:
Financial liabilities fair value	24.4
5.75% Senior convertible notes due October 23, 2021 | Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	19.8
5.75% Senior convertible notes due August 15, 2018
Financial liabilities:
Financial liabilities fair value		22.9
5.75% Senior convertible notes due August 15, 2018 | Carrying Value
Financial liabilities:
Financial liabilities fair value		27.6
5.75% Senior convertible notes due August 15, 2018 | Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value		22.9
2019 Notes and Tranche B Notes
Financial liabilities:
Financial liabilities fair value	54.6	74.5
2019 Notes and Tranche B Notes | Carrying Value
Financial liabilities:
Financial liabilities fair value	52.7	71.3
2019 Notes and Tranche B Notes | Estimate of Fair Value Measurement | Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	$ 54.6	$ 74.5

Fair Values of Financial Assets

Fair Values of Financial Assets and Liabilities Carried at Fair Value (Detail) - USD ($) $ in Thousands	Sep. 29, 2017	Dec. 31, 2017	Dec. 31, 2016
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair values of financial liabilities, beginning balance		$ 123,200
Settlement through exchange of common shares	$ (1,900)	(1,880)
Fair values of financial liabilities, ending balance		93,500	$ 123,200
Assets Held for Sale
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair values of financial assets, beginning balance		16,700	0
Additions		0	17,300
Changes in fair value		0	(600)
Payments		(16,700)	0
Fair values of financial assets, ending balance		0	16,700
Warrant Liability
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair values of financial liabilities, beginning balance		7,400	0
Additions		0	12,800
Changes in fair value		(5,500)	(5,400)
Settlement through exchange of common shares		(1,900)
Payments		0	0
Fair values of financial liabilities, ending balance		$ 0	$ 7,400

Common and Preferred Stock - Ad

Common and Preferred Stock - Additional Information (Detail)	Oct. 23, 2017shares	Oct. 10, 2017USD ($)$ / sharesshares	Mar. 01, 2017shares	Nov. 16, 2015shares	Nov. 12, 2015	Nov. 30, 2017USD ($)$ / sharesshares	Nov. 30, 2015USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 13, 2017$ / sharesshares	Sep. 30, 2016shares	May 31, 2016$ / shares	Nov. 09, 2015shares	Oct. 23, 2015shares
Class of Stock [Line Items]
Common stock, shares authorized			140,000,000					280,000,000	140,000,000			280,000,000	700,000,000
Common stock, par value | $ / shares								$ 0.01	$ 0.01			$ 0.01
Undesignated preferred stock, shares authorized								10,000,000	10,000,000			10,000,000
Undesignated preferred stock, par value | $ / shares								$ 0.01	$ 0.01			$ 0.01
Common stock, shares issued								119,053,414	95,680,831
Common stock, shares outstanding								119,053,414	95,680,831
Undesignated preferred stock, shares outstanding								0	0
Amount of net proceeds from issuance of securities | $								$ 564,000		$ 28,392,000
Stock split of common stock			0.2
Reverse stock split, description								The Company’s board of directors approved a 1-for-5 reverse stock split of its outstanding common stock. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
Common stock shares sold aggregate price | $								$ 564,000		27,843,000
Issuance costs associated with the Tel Aviv Stock Exchange | $								$ 17,000		548,000
Percentage of shares of common stock issued for offering				1.15%
Restricted warrants issued to purchase number of common stock for offering				32,000				32,000
Exercise price of restricted warrants per share in connection with the offering | $ / shares								$ 13.05						$ 7.50
Warrants exercisable period								5 years
Common stock loaned under share lending agreement, shares											1,800,000
Principal amount | $								$ 157,800,000
Nominal lending fee | $ / shares											$ 0.05
Returned shares of common stock under share lending agreement																1,800,000
Proceeds from exercise warrants | $									$ 0	10,123,000
Warrants expiration, date								Feb. 8, 2016
Senior convertible notes due August 15, 2015
Class of Stock [Line Items]
Principal amount | $											$ 100,000,000
TEL AVIV STOCK EXCHANGE
Class of Stock [Line Items]
Common stock, shares authorized															10,000,000
Number of shares sold during the period							2,770,487
Percentage of shares price per share					97.00%
Common stock shares sold aggregate price | $							$ 34,710,000			34,710,000
Share price | $ / shares							$ 13.05
Issuance costs associated with the Tel Aviv Stock Exchange | $							$ 1,432,000			$ 1,432,000
Common Stock
Class of Stock [Line Items]
Number of shares sold during the period	973,236							173,000		1,788,000
Stock split of common stock			0.2
Reverse stock split, description								On March 1, 2017, the Company effected a 1-for-5 reverse stock split of the Company’s outstanding common stock. As a result, prior to March 1, 2017, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
Common stock shares sold aggregate price | $								$ 2,000		$ 18,000
Common stock loaned under share lending agreement, shares										1,800,000
Common Stock | TEL AVIV STOCK EXCHANGE
Class of Stock [Line Items]
Number of shares sold during the period										2,771,000
Common stock shares sold aggregate price | $										$ 28,000
Purchase Agreements
Class of Stock [Line Items]
Stock purchase agreements date		Oct. 10, 2017
Placement agent fees		5.00%
Purchase Agreements | Common Stock
Class of Stock [Line Items]
Number of shares sold during the period		10,166,600
Exchange price per share | $ / shares		$ 6
Amount of net proceeds from issuance of securities | $		$ 57,700,000
Charitable Foundation | Common Stock | Chairman of Board of Directors
Class of Stock [Line Items]
Number of shares sold during the period		166,600
At Market Issuance Sales Agreement | FBR Capital Markets & Co. | Common Stock
Class of Stock [Line Items]
Number of shares sold during the period						173,327
Exchange price per share | $ / shares						$ 3.15
Amount of net proceeds from issuance of securities | $						$ 500,000
Minimum
Class of Stock [Line Items]
Common stock, shares authorized												140,000,000
Maximum
Class of Stock [Line Items]
Common stock, shares authorized												280,000,000

Net Income (Loss) per Common 57

Net Income (Loss) per Common Share - Additional Information (Detail)	Dec. 31, 2015shares
Earnings Per Share [Abstract]
Common shares loaned under the share lending arrangement, issued and outstanding	1,800,000

Components of Basic and Diluted

Components of Basic and Diluted Net Income (Loss) Per Common Share Computations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Basic EPS:
Net (loss) income (numerator)	$ (32,784)	$ (32,886)	$ (35,339)	$ (16,324)	$ 53,976	$ 126,520	$ (29,959)	$ (24,873)	$ (117,333)	$ 125,664	$ (368,445)
Weighted average common shares (denominator)	116,451,000	104,703,000	99,864,000	95,744,000	95,676,000	95,627,000	91,061,000	85,771,000	104,245,000	92,053,000	81,233,000
Net (loss) income per share - basic	$ (0.28)	$ (0.31)	$ (0.35)	$ (0.17)	$ 0.56	$ 1.32	$ (0.33)	$ (0.29)	$ (1.13)	$ 1.37	$ (4.54)
Diluted EPS:
Net (loss) income (numerator)	$ (32,784)	$ (32,886)	$ (35,339)	$ (16,324)	$ 53,976	$ 126,520	$ (29,959)	$ (24,873)	$ (117,333)	$ 125,664	$ (368,445)
Weighted average common shares (denominator)	116,451,000	104,703,000	99,864,000	95,744,000	95,676,000	95,627,000	91,061,000	85,771,000	104,245,000	92,053,000	81,233,000
Effect of dilutive securities - common shares issuable										32,000
Adjusted weighted average common shares (denominator)	116,451,000	104,703,000	99,864,000	95,744,000	96,510,000	96,548,000	91,061,000	85,771,000	104,245,000	92,085,000	81,233,000
Net (loss) income per share - diluted	$ (0.28)	$ (0.31)	$ (0.35)	$ (0.17)	$ 0.56	$ 1.31	$ (0.33)	$ (0.29)	$ (1.13)	$ 1.36	$ (4.54)

Potential Dilutive Securities O

Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	15,268,444	16,831,953	5,980,235
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	7,089,440	5,530,256	3,955,845
Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	6,875,272	814,561	814,561
Employee Stock Purchase Plan
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	136,660	43,672	33,986
Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	31,856	9,740,597	814,919
Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	1,135,216	702,867	360,924

Stock Award Plans - Additional

Stock Award Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	May 23, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved under ESPP	10.00%
Shares sold to employees		199,578	104,758	64,245
Shares purchased under ESPP		136,660
Options to purchase common stock		7,089,440	5,530,256
Stock-based compensation		$ 4,847	$ 5,135	$ 8,725
Weighted average grant date fair value of the stock options granted		$ 1.19	$ 3.05	$ 12.80
Total intrinsic value of options exercised			$ 100	$ 6,200
Cash received from the exercise of options		$ 20	500	3,300
Weighted-average remaining contractual term, options outstanding		6 years 10 months 13 days
Weighted-average remaining contractual term, options vested and expected to vest		6 years 9 months
Weighted-average remaining contractual term, options excerisable		3 years 6 months 25 days
Restricted stock units expected to vest		939,240
Weighted average grant date fair value		$ 4.28
Total intrinsic value of restricted stock units expected to vest		$ 2,200
Total intrinsic value of restricted stock units vested		400	600	5,200
Fair value of restricted stock units vested		$ 1,900	2,600	5,500
Weighted average vesting period for unrecognized compensation expense		2 years 3 months 18 days
Stock compensation expense		$ 4,847	5,135	8,725
Consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase common stock		23,047
Stock-based compensation				318
Executive Officer | Employee Severance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense				$ 1,600
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		36 months
Vesting rights percentage		25.00%
Unrecognized compensation expense related to options		$ 2,900
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Restricted Stock | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting rights percentage		25.00%
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to non-option		$ 3,200
Performance-based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to options		3,500
Compensation cost		$ 900	$ 300
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share of common stock outstanding	1.00%
Vesting period		4 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		10 years
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity incentive plan, shares					4,300,000
Options to purchase common stock		5,795,035
Employee Stock Purchase Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	400,000	246,205
Share reserve automatic increase each year	140,000

Stock Based Award Plans (Detail

Stock Based Award Plans (Detail) - shares	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	7,089,440	5,530,256
Outstanding Restricted Stock Units	1,135,216	737,966
Shares Available for Future Issuance	1,509,343
2004 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	1,231,740
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	5,795,035
Outstanding Restricted Stock Units	1,135,216
Shares Available for Future Issuance	1,509,343
2004 Non Employee Directors Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	62,665

Stock Based Compensation Expens

Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operation (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 4,847	$ 5,135	$ 8,725
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 4,847	$ 5,135	8,407
Consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation			$ 318

Stock Based Compensation Expe63

Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 4,847	$ 5,135	$ 8,725
Cost of Sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	460	695
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	1,010	1,309	3,029
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 3,377	$ 3,131	$ 5,696

Fair Value of Employee Stock Op

Fair Value of Employee Stock Options Assumptions (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Risk free interest rate, minimum	1.83%	1.18%	1.61%
Risk free interest rate, maximum	2.13%	1.80%	1.86%
Volatility, minimum	83.32%	77.57%	69.76%
Volatility, maximum	90.39%	82.75%	71.84%
Minimum
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected lives	5 years 4 months 28 days	5 years 1 month 16 days	5 years 9 months 14 days
Maximum
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected lives	5 years 9 months 10 days	5 years 9 months 25 days	5 years 10 months 10 days

Summary of Stock Options Outsta

Summary of Stock Options Outstanding (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
Number of Shares
Outstanding at January 1, 2017 | shares	5,530,256
Granted | shares	3,335,385
Exercised | shares	(5,300)
Forfeited | shares	(598,204)
Expired | shares	(1,172,697)
Outstanding at December 31, 2017 | shares	7,089,440
Vested and expected to vest at December 31, 2017 | shares	6,735,675
Exercisable at December 31, 2017 | shares	2,813,227
Weighted Average Exercise Price per Share
Outstanding at January 1, 2017 | $ / shares	$ 16.10
Granted | $ / shares	1.60
Exercised | $ / shares	4.55
Forfeited | $ / shares	3.17
Expired | $ / shares	22.21
Outstanding at December 31, 2017 | $ / shares	9.33
Vested and expected to vest at December 31, 2017 | $ / shares	9.70
Exercisable at December 31, 2017 | $ / shares	$ 19.52
Aggregate Intrinsic Value
Outstanding at December 31, 2017 | $	$ 2,484
Vested and expected to vest at December 31, 2017 | $	2,262
Exercisable at December 31, 2017 | $	$ 61

Summary of Restricted Stock Uni

Summary of Restricted Stock Unit Activity (Detail)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Number of Shares
Outstanding at January 1, 2017 | shares	737,966
Granted | shares	669,091
Vested | shares	(192,361)
Forfeited | shares	(79,480)
Outstanding at December 31, 2017 | shares	1,135,216
Weighted Average Grant Date Fair Value per Share
Outstanding at January 1, 2017 | $ / shares	$ 8.40
Granted | $ / shares	1.36
Vested | $ / shares	10.02
Forfeited | $ / shares	5.89
Outstanding at December 31, 2017 | $ / shares	$ 4.08

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) € in Millions	Nov. 29, 2017USD ($)	May 05, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Oct. 01, 2018USD ($)	Jul. 01, 2013USD ($)
Commitments And Contingencies [Line Items]
Purchase commitment amount under Insulin Supply Agreement | €				€ 90.3
Purchase commitment cancellation fees			$ 1,400,000
Purchase obligation included in accounts payable			$ 1,600,000
Supply Agreement expiration period			Dec. 31, 2023	Dec. 31, 2023
Supply Agreement renewal period			2 years	2 years
Purchase commitment obligation			$ 109,300,000			$ 116,200,000
Operating lease rent expenses			400,000		$ 400,000	$ 400,000
Supply Commitment
Commitments And Contingencies [Line Items]
Purchase commitment obligation			400,000
Scenario Forecast
Commitments And Contingencies [Line Items]
Purchase commitment cancellation fees							$ 3,400,000
Scenario Forecast | Before Amendment
Commitments And Contingencies [Line Items]
Purchase commitment cancellation fees							$ 5,300,000
Deerfield | Milestone Rights Liability | Maximum
Commitments And Contingencies [Line Items]
Contingent liability for milestone payments			$ 90,000,000					$ 90,000,000
Russell Ranch Road II LLC [Member]
Commitments And Contingencies [Line Items]
Operating lease rent expenses	$ 35,969	$ 40,951
Percentage of annual increase in lease payment	3.00%	3.00%
Lease expiration date	Jan. 31, 2023	Jan. 31, 2023
Lease renewal option	5 years	5 years
Maximum reimbursable amount for tenant improvements	$ 56,325

Annual Purchase Requirements un

Annual Purchase Requirements under Contract (Detail) € in Millions	Dec. 31, 2017EUR (€)
Annual Purchase Requirements under Contract
2,018	€ 8.9
2,019	11.6
2,020	15.5
2,021	15.5
2,022	19.4
2,023	€ 19.4

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Detail)	Dec. 31, 2017USD ($)
Leases [Abstract]
2,018	$ 522,000
2,019	947,000
2,020	976,000
2,021	1,005,000
2,022	1,035,000
Thereafter	88,000
Total	$ 4,573,000

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Employer contribution savings retirement plan	$ 0.4	$ 0.4	$ 0.6

Loss from Continuing Operations

Loss from Continuing Operations Before Provision for Income Tax (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
US	$ (113,679)	$ 129,361	$ (358,047)
Foreign	(3,603)	(3,697)	(10,398)
(Loss) income before income tax expense	$ (117,282)	$ 125,664	$ (368,445)

Income Taxes -Additional Inform

Income Taxes -Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 31, 2004	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Provision for income taxes					$ 51	$ 0	$ 0
Valuation allowance of deferred tax asset		$ 654,298			654,298	914,498
Change in the valuation allowance					(260,200)	(48,100)
Federal operating loss carryforwards		2,000,000			2,000,000
State operating loss carryforwards		2,200,000			2,200,000
Net operating loss carryforwards	$ 216,000
Net operating loss and credit carryforwards, annual use limitation	$ 13,000
Research and development credits		83,461			83,461	$ 77,998
Undistributed earnings from its foreign subsidiaries		0			$ 0
Effective income tax rate					35.00%	35.00%	35.00%
Additional income tax expense or benefit		0			$ 0
Reduction for employee remuneration					301,000
Decrease in valuation allowance					301,000
Provisional amount recorded related to mandatory deemed repatriation of foreign earnings					0
Scenario Forecast
Income Taxes [Line Items]
Effective income tax rate				21.00%
ASU 2016-09
Income Taxes [Line Items]
Attributable to excess tax benefits on stock compensation			$ 10,800
Federal
Income Taxes [Line Items]
Research and development credits		55,100			$ 55,100
Federal research and development credits begin to expire					2,024
State
Income Taxes [Line Items]
Research and development credits		$ 28,400			$ 28,400

Provision for Income Taxes (Det

Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current
U.S. federal	$ 51	$ 0	$ 0
U.S. state	0	0	0
Non-U.S.	0	0	0
Total current	51	0	0
Deferred
U.S. federal	244,801	(43,814)	109,512
U.S. state	15,398	(4,311)	(29,394)
Non-U.S.	0	0	0
Total deferred	260,199	(48,125)	80,118
Valuation allowance	(260,199)	48,125	(80,118)
Total	$ 51	$ 0	$ 0

Components of Net Deferred Tax

Components of Net Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 507,235	$ 712,124
Research and development credits	83,461	77,998
Capitalized research	1,016	5,117
Milestone Rights	1,908	3,242
Accrued expenses	211	440
Loss on purchase commitment	23,654	36,775
Non-qualified stock option expense	7,004	17,331
Capitalized patent costs	5,194	8,781
Other	795	7,380
Depreciation	23,820	45,310
Total net deferred tax assets	654,298	914,498
Valuation allowance	(654,298)	(914,498)
Net deferred tax assets	$ 0	$ 0

Effective Income Tax Rate (Deta

Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal tax benefit rate	35.00%	35.00%	35.00%
Permanent items	6.20%	(1.90%)	0.00%
Intercompany transfer of intellectual property	0.00%	0.90%	(1.00%)
2017 tax law changes	(265.00%)	0.00%	0.00%
Stock based compensation	(5.00%)	0.00%	0.00%
Tax attribute expirations	(2.80%)	0.00%	0.00%
Valuation allowance	231.60%	(34.00%)	(34.00%)
Effective income tax rate	0.00%	0.00%	0.00%

Warrants - Additional Informati

Warrants - Additional Information (Detail) $ / shares in Units, $ in Thousands	Oct. 23, 2017shares	Sep. 29, 2017USD ($)WarrantHoldershares	May 31, 2016USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2015USD ($)shares	Oct. 03, 2017shares	Nov. 16, 2015shares
Class Of Warrant Or Right [Line Items]
Fair value of shares sold with warrants | $			$ 44,700	$ 20,593	$ 8,253
Exercise price of warrants | $ / shares			$ 7.50	$ 13.05
Outstanding warrants				32,000			32,000
Adjustment of warrant liability | $		$ 1,900		$ 1,880
Common Stock
Class Of Warrant Or Right [Line Items]
Number of shares sold in underwritten public offering	973,236			173,000	1,788,000
Shares issuable under warrants granted						1,292,510
A Warrants
Class Of Warrant Or Right [Line Items]
Class of warrants expiration period upon issuance			2 years
B Warrants
Class Of Warrant Or Right [Line Items]
Class of warrants expiration period upon issuance			30 months
Warrants exercisable date			2017-05
Warrant Exchange Agreement
Class Of Warrant Or Right [Line Items]
Number of warrant holders | WarrantHolder		4
Outstanding warrants		9,700,000
Maximum | A Warrants
Class Of Warrant Or Right [Line Items]
Warrants to purchase of common stock			7,281,553
Maximum | B Warrants
Class Of Warrant Or Right [Line Items]
Warrants to purchase of common stock			2,427,184
Registered Offering
Class Of Warrant Or Right [Line Items]
Number of shares sold in underwritten public offering			9,708,737

Restructuring Charges - Additio

Restructuring Charges - Additional information (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost And Reserve [Line Items]
Restructuring	$ 362	$ 1,376	$ 3,028
Accrued Expenses and Other Current Liabilities
Restructuring Cost And Reserve [Line Items]
Restructuring	$ 400	$ 1,400

Reconciliation of Beginning and

Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost And Reserve [Line Items]
Accrual - Beginning balance	$ 1,376	$ 3,028
Costs incurred and charged to expense		2,035
Costs paid or settled	(1,014)	(3,687)
Accrual - Ending balance	362	1,376
Twenty Sixteen Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Accrual - Beginning balance	209
Costs incurred and charged to expense		1,475
Costs paid or settled	(209)	(1,266)
Accrual - Ending balance		209
Twenty Fifteen Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Accrual - Beginning balance	1,167	3,028
Costs incurred and charged to expense		560
Costs paid or settled	(805)	(2,421)
Accrual - Ending balance	$ 362	$ 1,167

Selected Quarterly Financial 79

Selected Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 4,530	$ 2,043	$ 2,163	$ 3,009	$ 12,404	$ 162,354			$ 11,745	$ 174,758
Net income (loss)	$ (32,784)	$ (32,886)	$ (35,339)	$ (16,324)	$ 53,976	$ 126,520	$ (29,959)	$ (24,873)	$ (117,333)	$ 125,664	$ (368,445)
Net income (loss) per share — basic	$ (0.28)	$ (0.31)	$ (0.35)	$ (0.17)	$ 0.56	$ 1.32	$ (0.33)	$ (0.29)	$ (1.13)	$ 1.37	$ (4.54)
Net income (loss) per share — diluted	$ (0.28)	$ (0.31)	$ (0.35)	$ (0.17)	$ 0.56	$ 1.31	$ (0.33)	$ (0.29)	$ (1.13)	$ 1.36	$ (4.54)
Weighted average common shares used to compute basic net income (loss) per share	116,451	104,703	99,864	95,744	95,676	95,627	91,061	85,771	104,245	92,053	81,233
Weighted average common shares used to compute diluted net income (loss) per share	116,451	104,703	99,864	95,744	96,510	96,548	91,061	85,771	104,245	92,085	81,233

Selected Quarterly Financial 80

Selected Quarterly Financial Data - Additional Information (Detail) - USD ($) $ in Thousands	Nov. 09, 2016	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Interim Reporting [Line Items]
Net revenue - collaboration					$ 250	$ 171,965
(Loss) gain on extinguishment of debt					(1,611)	72,024	$ (1,049)
Net revenue - commercial product sales		$ 1,200			$ 9,192	1,895
License and Collaboration Agreement with Sanofi
Interim Reporting [Line Items]
(Loss) gain on extinguishment of debt	$ 500
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH
Interim Reporting [Line Items]
Net revenue - collaboration			$ 10,200	$ 161,800		$ 172,000
(Loss) gain on extinguishment of debt			$ 72,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Jan. 18, 2018USD ($)d$ / sharesshares	Jan. 15, 2018USD ($)	Oct. 23, 2017shares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2015shares	Dec. 13, 2017$ / shares	Jun. 29, 2017$ / shares	Apr. 18, 2017$ / shares	Dec. 31, 2016$ / sharesshares
Subsequent Event [Line Items]
Common stock, shares issued | shares				119,053,414					95,680,831
Common stock, par value				$ 0.01		$ 0.01			$ 0.01
Common Stock
Subsequent Event [Line Items]
Number of shares sold in underwritten public offering | shares			973,236	173,000	1,788,000
Senior convertible notes due December 31, 2019
Subsequent Event [Line Items]
Exchange price per share							$ 1.45	$ 1.22
Senior convertible notes due December 31, 2019 | Deerfield | Tranche B Exchange Shares
Subsequent Event [Line Items]
Exchange price per share								$ 1.15
Subsequent Event | Senior convertible notes due December 31, 2019 | Deerfield | Fifth Amendment to Facility Agreement
Subsequent Event [Line Items]
Deferred payment of credit facility principal amount | $		$ 4,400,000
Subsequent Event | Senior convertible notes due December 31, 2019 | Deerfield | Sixth Amendment to Facility Agreement
Subsequent Event [Line Items]
Deferred payment of credit facility principal amount | $	$ 1,250,000
Common stock, shares issued | shares	1,267,972
Common stock, par value	$ 0.01
Conversion of notes to common shares, value | $	$ 3,157,251
Exchange price per share	$ 2.49
Subsequent Event | Senior convertible notes due December 31, 2019 | Deerfield | Sixth Amendment to Facility Agreement | Tranche B Exchange Shares
Subsequent Event [Line Items]
Number of trading days | d	3
Conversion price of shares	$ 2.75
Subsequent Event | Senior convertible notes due December 31, 2019 | Deerfield | Sixth Amendment to Facility Agreement | Common Stock | Tranche B Exchange Shares
Subsequent Event [Line Items]
Number of shares sold in underwritten public offering | shares	10,000,000